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“Le bon sens de la vie humaine nous montre 
que la vie humaine est courte, et qu'il faut mieux faire 
de notre court passage sur terre quelque chose d'utile 
pour soi et pour les autres.”  
 
 
“Il buon senso ci indica che la vita umana è 
breve, e che è meglio trasformare il nostro fugace 











The U.S. Food and Drug Administration defines as Precision or Personalized Medicine (PM) an 
innovative therapeutic approach that tailors therapy and prevention on patients based on inter-individual 
variabilities in molecular or environmental features and in lifestyles. The major goals of PM are to maximize 
treatment efficacy and to reduce cost, toxicities and therapy failure rates by early identification of patients who 
might benefit or not of a specific treatment. In this scenario, therapeutic drug monitoring (TDM) is an important 
laboratory tool for PM because of the possibility to measure several drugs and bioactive molecules in human 
biological matrices. TDM is based on the hypothesis that in the majority of drugs, there is a relationship 
between administered dose and circulating concentration of unbound fraction - and between this concentration 
and observed pharmacological effects. TDM is recommended for drugs with significant inter-individual 
pharmacokinetic variability and an established relationship between blood concentrations and clinical efficacy 
and/or toxicity. Moreover, TDM is also advisable in special populations such as pregnant women and children. 
To date, liquid chromatography and immunometric assay are still considered the standard for molecule 
measurement in biological fluids; however, in recent years, LC tandem mass spectrometry (LC-MS) is gaining 
popularity because of the possibility of in-depth and multiplexed analysis with high selectivity and specificity.  
During this Ph.D. program, we developed several high performance LC (HPLC)- and LC-MS/MS-based 
approaches for TDM of different drugs measured in various types of body fluids and validated according to 
EMA and FDA guidelines. In particular, we focused on:  
1) TDM of hydroxychloroquine (HCQ) blood concentration, a drug with a wide therapeutic window. 
Our method was validated on a cohort of patients with Systemic Lupus Erythematosus treated with 
HCQ and blood concentrations were correlated to several clinical parameters, such quality of life. 
Moreover, TDM of HCQ was also used to monitor treatment adherence in those subjects. 
2) TDM of a commonly used chemotherapeutic agent, the 5-fluorouracil (5-FU), which is known to 
have a narrow therapeutic window and a high toxicity  
3) TDM of a new kinase inhibitor, Ruxolitinib, approved for the treatment of myeloproliferative 
hematologic disorders.  
4) TDM of several drugs, such as caffeine and phenobarbital, in newborns who are at particular risk of 
uncorrected drug dosage. Due to the need to carry out analyses on very-small volume samples, we 
validated an analytical method using micro-sampling techniques such as the dried blood spot (DBS) 





La U.S. Food and Drug Administration definisce con il termine Medicina di Precisione o 
Personalizzata (MP) un approccio terapeutico innovativo che identifica strategie terapeutiche e di 
prevenzione sul singolo paziente in base alla presenza di variazioni interindividuali in fattori 
biologici, ambientali e dello stile di vita. Gli obiettivi principali della MP sono quelli di aumentare 
l’efficacia terapeutica e di ridurre i costi, le tossicità e il tasso di fallimento terapeutico individuando 
precocemente i pazienti che possono beneficiare o meno di una specifica terapia. Il monitoraggio 
terapeutico dei farmaci (TDM) è quindi un importante strumento diagnostico per la MP perché 
permette di misurare farmaci e molecole bioattive in varie matrici biologiche. Il TDM si basa 
sull’ipotesi che per la maggior parte dei farmaci esiste un rapporto diretto tra dose somministrata e 
concentrazione circolante – e tra queste e l’effetto terapeutico. Per questo motivo, il TDM è 
raccomandato in tutti quei casi in cui sussiste una significativa variabilità farmacocinetica 
interindividuale ed una relazione nota tra concentrazioni plasmatiche ed effetto terapeutico o tossicità. 
Inoltre, il TDM è indicato anche in particolari popolazioni come le donne in gravidanza e i bambini. 
Ad oggi, la cromatografia liquida (LC) e le tecniche immunometriche sono ancora considerate lo 
standard per il dosaggio di molecole in fluidi biologici; tuttavia, negli ultimi anni, la LC accoppiata 
alla spettrometria di massa (LC-MS) sta rapidamente affiancando -e in alcuni casi soppiantando- le 
altre due tecniche grazie alla possibilità di effettuare analisi approfondite su numerose molecole in 
contemporanea, con alta selettività e specificità.  
Nell’ambito del presente progetto di dottorato, sono stati sviluppati numerosi metodi analitici 
con analisi in high performance LC (HPLC)- o LC-MS/MS per il TDM di varie molecole in fluidi 
biologici e validati seguendo le linee guida della EMA e della FDA. In particolare, l’attenzione è stata 
focalizzata su:  
1) TDM dell’idrossiclorochina (HCQ), un farmaco con un’ampia finestra terapeutica. Il 
metodo sviluppato è stato validato su una coorte di pazienti affetta da Lupus Eritematoso 
Sistemico in trattamento con HCQ e le concentrazioni plasmatiche sono state correlate con 
vari parametri clinici e con la qualità della vita. Inoltre, il TDM dell’HCQ è stato anche 
utilizzato per monitorare l’aderenza al trattamento di tali soggetti.  
2) TDM di un chemioterapeutico largamente utilizzato quale il 5-fluorouracile, caratterizzato 
da una stretta finestra terapeutica e da grave tossicità.  
3) TDM di un nuovo inibitore di chinasi, il Ruxolitinib, approvato per il trattamento di malattie 
ematologiche mieloproliferative. 
4) TDM di varie molecole quali caffeina e fenobarbital in neonati che sono particolarmente a 
rischio di dosaggi terapeutici non corretti. In particolare, data la necessità di lavorare su 
 
 
piccoli volumi, è stato messo a punto il TDM con metodica di micro-campionamento quale 











1.1 Going toward Personalized Medicine: the need of therapeutic drug monitoring 
 
 Genetic and epi-genetic differences between individuals may induce significant variability in 
drug response [1]. Consequently, a therapeutic treatment based on the “one-size-fits-all” concept, 
which ignores the widely inter-individual variation that exists in response to medication, can be 
ineffective or even damaging. Nowadays medicine strives towards personalized therapy and 
“personalized medicine” (PM), which stands for therapy adaptation to the molecular characteristics 
of patient and its disease (Figure 1) [2]. 
PM challenges are to identify and classify subgroups of patients who differ in their 
susceptibility to a particular disease or their response to a specific treatment. Preventing or therapeutic 
intervention can then be foreseen for those who will actually benefit, sparing expense and side effects 
for those who will not. [3]. PM definition, commonly accepted and taken over by the European 
Medicine Agency (EMA), consists in administrating “the right dose of the right drug to the right 
person at the right time” [4]. From Ayurvedic medicine to Hippocrates, the concept of PM has long 
been known [5-7].  
 Even if the PM idea is not new, its current application is quite recent. Since 1990s technical 
advances are part of a historical evolution of biology and biomedicine, leading to a new turning point 
in personalized medicine. Today, -omics technologies offer an access to different molecular profiles 
and disturbances of cellular signaling pathways which seeks to understand all the molecular 
underpinnings of drug response or posology [1,2]. PM may thus be considered as an extension of 
traditional approaches to understand and treat diseases, but with a greater precision [8]. Several other 
important aspects, such as the decreasing rate of new medical product development and the increasing 
of healthcare costs generated by both aging population who lives longer and the increasing 
hospitalization due to adverse drug reactions (ADRs), encouraged manufacturers, authority and 
government to invest on PM.  
ADRs are an important cause of morbidity and mortality worldwide, with a significant and 
increasing health and economic burden. Several meta-analysis studies conducted in the USA and in 
European countries found that the frequency of serious ADRs leading to hospitalization ranged, 
respectively, from 1.0 % to 16.8% and from 0.5% to 12.8%. Among hospitalized patients, the global 
incidence of serious ADRs was 6.7% and that of fatal ADRs was of 0.32% [9,10]. From 1999 to 
2006, national USA Vital Statistics System data have shown that the rate of ADR-related deaths 
increased from 0.08 to 0.12 per 100,000 persons [11]. In the UK, an historical study on 20,000 
hospitalized patients found that ADRs resulted in an average of eight days of hospital stay and were 
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associated with approximately € 706 million per year, including ADRs judged potentially avoidable. 
[12].  
 
Another problem that healthcare system faces is the limited effectiveness of numerous 
treatments, especially those regarding chronic diseases. A substantial inter-variability to drug 
response in oncology field as well as for common conditions like hypertension, heart failure, 
depression, hypercholesterolemia and asthma, has indeed been observed [13,14]. As a result, the 
ability to rapidly discriminate between patients who will benefit from a given treatment and those 
who are at risk of significant adverse events could result in significant cost savings for the entire 
health system. 
In this scenario, therapeutic drug monitoring would be a cheap and widely-applicable armored 
PM arm because, by using common simple instrumentations, such as liquid chromatography, or more 
complex apparatus, such as mass spectrometers, clinicians can rapidly adjust theoretical drug doses 
Figure 1. Personalized medicine. Personalized medicine promises to transform the delivery of healthcare to patients. 
Its aim is to evolve from a reactive “one-size-fits-all” system towards a system of predictive, preventive, and precision 
care. This picture depicts how personalized medicine could classify people into smaller subsets based on the therapy 
response from one large disease group. Genetic tests can help stratify patients in those who would respond effectively 




in single patients in order to maintain an effective and safe serum/plasma trough concentration by 
maximizing efficacy while minimizing ADR incidence. 
The need of PM tailored on each patient is of growing interest in scientific and non-scientific 
communities: the creation of several large-scale international projects such as the "Personalized 
Medicine Coalition", the "Genomics and Personalized Medicine Act" as well as ministerial 
commissions throughout Europe, demonstrate the growing interest of physicians, researchers, 
industry and government for this topic. However, we are still far from a real PM as many different 
fields need to deeply collaborate in order to combine epidemiology, genomics, molecular biology, 
proteomics, and metabolomics fingerprints which all might affect drug response in patients.  
 
1.2 Variability in drug response  
1.2.1 Biomarkers 
 
The individual’s response to a drug depends on the complex interplay between environmental 
and genetic factors. There are multiple contributory factors which play a role in the drug response 
variability such as gender, age, diet, body mass, health status, epigenetic factors, concurrent therapy 
or environmental exposure to certain chemicals or toxins (e.g. cigarette smoke) [1,15]. To identify 
the ideal treatment and to adapt it to each patient it is therefore necessary to use specific tools to 
measure accurately and reproducibly the clinical manifestations of patient's health status. It was in 
1998 that the word biomarker was defined for the first time by the National Institute of Health as “a 
characteristic that is objectively measured and evaluated as an indicator of normal biological 
processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.” Even if 
biomarker use has been known for long time, recent advances in new high-speed technologies as 
genomic platforms, high-performance biochips or new generation of mass spectrometry, increase 
possibilities to identify new biomarkers for precocious diagnosis, prognosis and therapeutic 
monitoring [16]. 
Biomarkers are physiological, biochemical or molecular parameters that can be detected in tissue 
or biological fluids such as blood, urine, etc. Today, biomarkers represent a vast field that covers 
different areas of application ranging from pharmaceutical development to clinical medicine. [17,18]. 
They can be classified into three categories: prognostic, used to predict the natural course of a 
confirmed disease; predictive, used to predict the response of patient to a drug; pharmacodynamic, 
used to evaluate efficacy or toxicity to treatment and to modulate drug dosing. Predictive biomarkers 
are mainly used in hematology and oncology and consider both conventional environmental factors 
and dose selection. Indeed, immunohistochemistry tests such as Her2 protein in breast cancer or 
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pharmacogenomics tests as the dihydropyrimidine dehydrogenase (DPYD) test for 5-fluorouracil 
make it possible to identify patients with a pharmacokinetic/pharmacodynamic (PK/PD) risk such as 
ADRs or inefficient treatment [19]. 
 
1.2.2 Pharmacogenomics and pharmacogenetics 
 
Genetic variations can affect how the body responds to certain medications [20]. Two main 
types of inter-individual variations have been found in the genome i.e. variable number tandem 
repeats (VNTRs) which occur in the non-coding DNA and is used for paternity testing, forensic 
science or DNA fingerprinting and single nucleotide polymorphisms (SNPs), which are the most 
important source of genome variation. These latter contribute for 0.1% of differences retrieved in 
gene sequences and are at the origin of interindividual variabilities; SNPs can lead to protein 
modifications that may be responsible of alteration of their stability, cell concentrations, metabolic 
activity or signaling properties [21].  
Pharmacogenetics takes its first steps in the ‘50s and brings genetics, biochemistry, and 
pharmacology together. The first person to have mentioned that genetic variants can modulate drug 
action is the physiologist Garrod. Thereafter, a tide of reports suggested that ADRs could be 
genetically determined variations in enzyme activity. For example, hemolysis caused by antimalarials 
was recognized as being caused by inherited variants of glucose-6-phosphate dehydrogenase. 
Similarly, inherited changes in DPYD gene leading to low enzyme activity produce a greater 
bioavailability of the antimetabolite 5-fluorouracile, thus causing serious hematological, neurological 
and gastrointestinal toxicities. However, it was only after 1959 that F. Vogel proposed the term 
pharmacogenetics, which is defined as the study of the influence of genome variability in drug 
response [22]. Pharmacogenetics is aimed at determining the genetic differences in metabolic 
pathways that can affect individual responses to drugs [23]. In pharmacogenetics, the analysis of a 
specific gene, or group of genes, can be used to predict responses to a specific drug or class of drugs. 
However, rarely a single gene directly controls drug response or ADRs and advances in 
pharmacogenetics have remained limited. Emergence and development of Human Genome Project 
and genome science in 1990s [24] have then spawned a newer field, named pharmacogenomics [25]. 
The main aim of pharmacogenomics is to understand all of the molecular underpinnings of drug 
response. Pharmacogenomics carries the idea that variable drug response may reflect sets of variants 
within an individual or across a population. Pharmacogenomics is a broader application of genomic 
technologies for development of new drug and / or further categorization of existing drugs [26]. Even 
if current uses of pharmacogenomics are limited, it still offers new perspectives for the next years 
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including i) a better medication selection, predicting patients with risk of ADRs and those who will 
be likely to respond successfully, ii) a safer dosing option, since in some cases parameters approval 
of FDA is not sufficient, iii) improvements in drug development by reducing time and cost of R&D, 
thus preventing unsuccessful clinical trials and targeting a specific population for one specific 
medication. 
Today, the boundary between pharmacogenetics and pharmacogenomics remains unclear and 
the debate in the scientific community is still very active. Indeed, both terms are often used 
interchangeably, and a unanimous and precise definition of either remains elusive [27]. 
 
1.2.3 Pharmacokinetics and Pharmacodynamics 
 
Pharmacokinetic (PK) and Pharmacodynamic (PD) determine the clinical effect of drug 
therapy and can be resumed in what the organism does to the drug and what the drug does to the 
organism, respectively. Once a drug is administered, it is absorbed and distributed to its site of action, 
where it interacts with the target(s). Intensity and duration of drug response is determined not only 
by the PK processes, but also by the PD ones. Therefore, the variability in drug response is a result 
of the variability in either PK or PD processes, or a combination of both [28].  
PK depends on the relationship between drug effective concentration in the body and its dose. 
Molecular mechanisms leading to a specific PK were summarized in the acronym L.A.D.M.E. that 
includes liberation phases, absorption, distribution, metabolism and excretion of the drug. Today, 
several evidences demonstrated the key role played by the patient’s compliance, which should be 
considered as an additional parameter, thus leading to the more complete current acronym 
C.L.A.D.M.E.  
Drug action begins with its administration and depends on its absorption pathway, which may 
be oral, intramuscular, subcutaneous or topical/transdermal. Obviously, the patient has an active role 
in the correct application of the therapeutic regimen; compliance concept describes the patient 
adherence degree with respect to medical prescriptions, and consequently underlines patient's 
responsibility in the success of any therapy [29]. Following drug administration, the bioactive 
compound must be liberated from its release system. Pharmaceutical formulation, physiochemical 
features of the drug - such as molecular weight and hydrophilicity/lipophilicity-, and the type of 
environment at the site of administration strongly influence the liberation process. Drug absorption 
mechanisms may be different before reaching the bloodstream: passive diffusion (para-cellular or 
facilitated), active transport and transcytosis. After absorption, the drug reaches the circulation and is 
distributed at the various compartments of the organism. Again, drug-related factors (e.g. molecular 
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size, acid dissociation constant…), the presence and location of drug transporters, protein binding 
(albumin and acid α1-glycoprotein), systemic pH, and tissue perfusion influence the distribution. 
Other parameters, as body composition in fat or water, nutritional and health status or age, have some 
effects on the drug distribution volume. Consequently, the way in which the drug will be distributed 
will affect drug concentration and consequently the PD. Within organism, a drug undergoes various 
metabolic processes, mainly occurring in the liver. These processes have the role to enzymatically 
transform the drug making it more hydrophilic and facilitating its excretion. Drug metabolism is 
mainly performed in two phases. Phase I enzymes introduce reactive or polar groups and are catalyzed 
by the superfamily of cytochrome (CYP)-450 monooxygenases. These enzymes catalyze reactions as 
oxidation, reduction, hydrolysis or hydroxylation. Phase II enzymes perform conjugation reactions 
such as glucuronidation, sulfonation, methylation. Phase II are synthetic reactions catalyzed by 
several enzymes, and are aimed at transforming metabolites in more polar compounds that can be 
more easily excreted. Phase I and phase II processes are also responsible for the so called "first pass 
effect" and the enterohepatic circulation. The ultimate step of C.L.A.D.M.E. consists of elimination 
phase, which is composed of two main routes: the renal route –characterized by glomerular filtration 
and tubular secretion - and the hepatic route. Elimination phase regulates the half-life of each drug, 
which corresponds to the time required to observe a decrease of fifty percent in the maximum 
plasmatic concentration obtained for that specific drug.  
All these processes contribute in the definition of the bioavailability concept, which is the 
drug amount (expressed as percentage) in its active form that reaches the systemic circulation and 
can, then, reach the action site. After a single drug administration, monitoring of plasma concentration 
over the time allows to obtain PK parameters important to define the bioavailability concept such as 
the maximum concentration (Cmax) corresponding to a maximum time (Tmax), and the area under 












Figure 2. Typical bioavailability graph of an orally administrated drug. 
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Once undergone the different PK processes, the active principle reaches the target and can 
carry out its action on the biological systems thus determining the PD events. PD describes the 
relationship between drug concentration and the pharmacological action, including ADRs. Some 
drugs exert their function almost exclusively due to their chemical and physical characteristics; 
nevertheless, they generally interact with specific macromolecular systems like receptors, target 
proteins or ion channels, modulating or inhibiting normal biochemical processes. Drug-receptor 
interaction generate biochemical changes or physiological modifications that strongly influence drug 
response [31]. 
 
1.2.4  Pharmacokinetic and Pharmacodynamic variability 
 
The large interindividual variability in drug response represents a major challenge in drug 
therapy, particularly for drugs with a narrow therapeutic index. Genetic factors represent the most 
important source of interindividual variability in drug response. Unlike non-genetic factors, genetic 
factors generally remain stable throughout a person’s lifetime. Given the high SNP density, it is not 
surprising to see that virtually every protein involved in the drug PK and PD, such as drug-
metabolizing enzymes, transporters and receptors will be eventually found to have genetic variation. 
Although genetic polymorphisms in drug metabolizing enzymes have generally been known for more 
than 50 years, genetic polymorphisms for transporters and receptors have only recently received 
attention [32-35]. 
PHARMACOKINETIC VARIABILITY. Many factors can contribute to the marked variability 
among patients in their plasma profiles following a fixed oral dose, including genetic and non-genetic 
factors. The former includes genetic variability in drug-metabolizing enzymes and drug transporter 
systems and the latter comprise gastrointestinal physiology and diet. 
Genetic Variability in Drug-Metabolizing Enzymes. Genetic polymorphisms of drug-
metabolizing enzymes may significantly contribute to the interindividual and interethnic differences 
in drug disposition and represents a major challenge in drug development. However, it is important 
to point out that although polymorphisms of drug metabolizing enzymes are generally considered 
undesirable and might be problematic, they are manageable in most cases. In this context many 
members of  the superfamily of cytochrome P450 are involved such asCYP2D6, which has the largest 
phenotypic variation among the P450 enzymes, CYP2C19, whose impact has been highlighted by 
several studies and a meta-analysis in patients with coronary artery disease treated with the 
antiplatelet agent clopidogrel, CYP2C9, which is responsible for the metabolism of several drugs 
with narrow therapeutic indices (i.e. phenytoin and warfarin), and CYP3A4/CYP3A5 that, although 
accounting for approximately 30% of hepatic P450 content and being involved in over 50% of drug 
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metabolism, does not appear to have polymorphisms that result in absence of functional protein. 
Noteworthy, wide variability in CYP3A4 activity seems to be due in part to the large number of 
substrates capable of inhibiting or inducing the enzyme.  
Genetic variability in drug transporters. With few exceptions such as anticoagulant drugs 
that act directly in the blood compartment, most drugs have to be transported from blood circulation 
to the action site in target tissue(s) in order to exert their pharmacologic activity. Once a drug enters 
the systemic circulation, it readily crosses several cell membranes and reaches the intracellular fluids 
of almost every organ and tissue. There are many processes by which drugs cross cell membranes, 
including passive (simple) diffusion and transporter-mediated influx and efflux transport. Kinetically, 
cellular distribution of drugs can be viewed as a two-step process arranged in series by influx (uptake) 
and efflux transport. Drug concentration in cells is thus determined by the difference between the rate 
of influx and efflux transport [36]. The uptake transporters include organic anion transporting 
polypeptide (OATP), organic anion transporter (OAT), and organic cation transporter (OCT) 
subfamilies, while the efflux transporters include multidrug resistance protein (P-glycoprotein; 
MDR1), multidrug resistance-related protein (MRP), and the breast cancer resistance protein (BCRP) 
families [37-42]. In the past 10 years, genetic polymorphisms have been identified for many uptake 
and efflux transporters, and there is increasing evidence that genetic polymorphisms in transporters 
may also contribute to drug absorption, disposition and response.  
Although in general the effect of transporter polymorphisms on drug pharmacokinetics 
appears to be quantitatively less significant compared to that of drug metabolizing enzymes, the 
impact of transporter polymorphisms might be underestimated if the sole plasma concentration is 
monitored. An important lesson learned from the kinetic studies of transgenic animals is that genetic 
polymorphisms have a much greater impact on tissue distribution of drugs than on plasma 
concentration of drugs [43,44]. Therefore, together with the genetic polymorphisms of drug 
metabolizing enzymes, one should carefully assess the impact of transporter polymorphisms on drug 
pharmacokinetics to better predict drug efficacy and toxicity.  
Non-genetic Pharmacokinetic Variability. Although genetic polymorphisms of both drug 
metabolizing enzymes and transporters are the major sources responsible for the observed 
interindividual variability in pharmacokinetics of drugs, many non-genetic factors, such as 
physiological, pathological and environmental factors, may also contribute significantly to the 
interindividual variability in ADME processes. Being absorbed primarily from the upper part of the 
small intestine, oral absorption of drugs is often affected by the gastric emptying time and small 
intestinal motility, which vary considerably between individuals, even within the same individual on 
different occasions [45,46]. Therefore, it is expected to see significant variations in oral absorption 
of drug at same dose level, and same formulation in the same subject during multiple drug dosing. 
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Both the rate and extent of drug absorption can vary considerably between individuals and within the 
same individual. Intraindividual variation in oral absorption is best exemplified by the study of 
azathioprine [47]. In a clinical study, the intraindividual (day-to-day) variability in the 
pharmacokinetics of azathioprine was determined in 10 renal transplant patients on two consecutive 
days after oral administration. In some patients, a 2- to 3-fold intraindividual difference in the AUC 
of azathioprine between the two days was retrieved. In this study, there was a 6-fold difference in the 
AUC between patients. Similarly, there was a 2- to 3-fold intraindividual variation in the AUC of 
cyclosporine in seven healthy volunteers after single oral doses on two occasions at 2-week interval 
[48]. Significant inter- and intra-individual variability in the oral AUC has also been reported for 
other drugs, such as nifedipine, doxorubicin, furosemide and chlorambucil [49-52]. Food intake has 
also a significant impact on drug absorption. Since the diet is so different among individuals, even 
within the same individual on daily basis, food intake is an important source responsible for the intra- 
and inter-individual variability in oral absorption of drugs. The effect of food on drug absorption is 
largely unpredictable. Depending on the type and size of a meal and the physicochemical properties 
of drugs, oral absorption of drugs may be reduced, delayed, increased, accelerated, or not affected by 
concomitant food intake [53,54]. Mechanisms related to food effects include direct effect on food-
drug interactions and indirect effect on gastrointestinal physiology. The degree of food-drug 
interactions are determined mainly by the composition of food and the physicochemical properties of 
drugs. Dietary components may influence the dissolution and solubility of drugs and subsequent 
absorption. In some cases, irreversible interactions between food components and drugs, such as 
complexation and chelation interactions between drugs and metal ions in meals, may occur and 
decrease absorption. In addition, food may act as a physical barrier, preventing drug access to the 
absorptive surface of the intestinal tract. For drugs that are highly soluble and highly permeable, oral 
absorption is usually less sensitive to food effects, particularly when given with rapidly dissolving 
and immediate-release formulations [55]. Food can influence both the rate and extent of drug 
absorption by indirectly altering gastrointestinal physiology. Although food generally tends to delay 
gastric emptying, it has a stimulating effect on intestinal motility [50,56]. Delayed gastric emptying 
will delay absorption of drugs that are absorbed rapidly from small intestine. On the other hand, 
delayed gastric emptying might increase systemic availability of drugs that have relatively poor 
solubility by permitting more material to dissolve in the stomach before passing into small intestine, 
while drugs that are unstable in acidic pH are likely to be degraded because of prolonged residence 
in the stomach. In addition, food intake increases the gastric secretion of hydrochloric acid, intestinal 
secretion of digestive enzymes and bile secretion. If a drug’s solubility is pH- or bile-dependent, 
hydrochloric acid and bile secretion will have significant effect on drug absorption as exemplified by 
indinavir and rufinamide [57,58]. In addition, food intake may increase the splanchnic blood flow 
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leading to an increase in the bioavailability of drugs by decreasing first-pass metabolism. The indirect 
effect of splanchnic blood flow on drug absorption is best exemplified by food effect on the 
absorption of propranolol. The splanchnic blood flow-mediated food effects have also been reported 
for other drugs as well [59-61]. Food may have direct effect on drug metabolism also by inducing 
and inhibiting drug metabolizing enzymes. The metabolic clearance of antipyrine and theophylline 
was increased in healthy subjects by a high-protein low-carbohydrate diet for 2 weeks, suggesting an 
increase in enzyme activity [62]. Certain vegetables, including brussel sprouts, cabbage, broccoli and 
cauliflower contain chemicals that induce drug metabolizing enzymes and decrease drug 
bioavailability [63]. The lower plasma concentrations of antipyrine and theophylline after digestion 
of charcoal-broiled meat is believed to be due to the induction of CYP1A1/2 through the 
contamination of polycyclic hydrocarbons resulting from the incomplete combustion of meat 
drippings [64]. On the other hand, food may inhibit drug metabolism enzymes. Drinking grapefruit 
juice is known to increase the oral bioavailability of some drugs in humans by decreasing intestinal 
CYP3A4 protein expression [65]. Recently, it has been reported that fexofenadine absorption was 
reduced by ingestion of grapefruit juice [66]. The reduction of fexofenadine absorption might be due 
to the inhibition of uptake transporter by grapefruit juice. 
In addition to food intake, environmental factors and pathophysiological changes, such as 
deterioration of renal function or progression of a chronic disease, could also contribute to the 
pharmacokinetic variability. 
PHARMACODYNAMIC VARIABILITY. Unlike the dose-concentration relationship, a clear 
concentration-response relationship cannot always be obtained, due to the complexity of disease 
pathogenesis and the difficulty in evaluating the effective pharmacological response. Therefore, the 
knowledge of the genetic causes responsible for the interindividual variability in pharmacological 
response is not as advanced as that described above for drug-metabolizing enzymes. 
Genetic Variability in Receptors. In spite of a large body of information on genetically 
polymorphic variations of receptor systems, our understanding about the pharmacologic 
consequences of these polymorphisms is still at early stage. There are still large gaps in our 
knowledge about how to utilize the information obtained from pharmacogenetic studies to explain 
the interindividual variability in drug response. First, many pharmacogenetic studies of the effect of 
receptor polymorphisms on drug response showed conflicting and inconsistent results. One of the 
reasons for the inconsistence is that most diseases have complex genetic traits, with multiple genetic 
and environmental components contributing to susceptibility. The complexity of gene-disease 
relationship can be best illustrated by a recent survey of genetic association studies. More than 600 
positive associations between genes and diseases were reported; 166 had been studied more than 3 
times, but only 3 had been consistently replicated [67]. These results strongly suggest that if the 
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disease-causing allele is not prevalent, it might not be easier to find a good relationship between a 
single genetic variant and drug response. Recent evidence suggests that determining haplotypes may 
be more informative than genotyping single variant in relating genetic factor to drug response [68]. 
The haplotypes of ß2-andrenergic receptor is a good example for predicting drug response [69]. While 
there was no association between the response to albuterol and any individual SNP of the ß2-
andrenergic receptor in isolation, the presence of 5 haplotypes predicted well the albuterol response 
(increase in FEV1) in patients with asthma. Other possible reasons for the conflicting reports on the 
effect of polymorphisms of drug receptors may be related to the methods of measuring drug response 
and the power of sample size of study. With the advance of bioanalytical technologies, the effect of 
polymorphism of drug metabolizing enzymes on the plasma concentration of drugs can be very 
accurately measured. In contrast, the measurement of pharmacologic response is generally less 
accurate. Therefore, the inaccurate measurement of drug response could contribute significantly to 
the conflicting reports. In addition, the number of patients needed to detect drug-gene interactions is 
highly dependent on the type of trait (discrete or continuous) and the precision of drug response 
measurement [70]. Complex traits require a large number of patients to establish the relationship of 
drug-gene interactions.  
Non-genetic Pharmacodynamic Variability. Although genetic polymorphisms of drug targets 
(receptors and enzymes) are the major sources responsible for the interindividual variability in 
pharmacodynamics, many nongenetic factors, such as psychological, pathological and environmental 
factors, may also contribute significantly to the interindividual variability in drug response. Among 
these non-genetic factors, psychological factor is probably the most intriguing aspect in drug 
treatment and represents a major source of non-genetic pharmacodynamic variability. In clinical 
trials, the pharmacologic response of a test drug is often evaluated against inactive substance known 
as placebo. Although the phenomenon underlying the placebo effect is not fully understood by 
science, it is believed that the placebo effect is psychological, due to a belief in the treatment. In 
contrast, a patient who disbelieves in a treatment may experience a worsening of symptoms, the so-
called “nocebo effect” [71]. The nocebo effect may compromise the drug action when active drug is 
given. Clearly, depending on the patient’s attitude towards the treatment, the effectiveness of the drug 
prescribed could be in more positive or negative direction.  The notion that the placebo-induced pain 
reduction is mediated by an endogenous opiate-related mechanism is supported by a recent study on 
a total of 1183 participants by Sauro and Greenberg [72]. Placebo administration was associated with 
a decrease in self-report of pain, and injection of naloxone, an opiate receptor antagonist, reversed 
placebo-induced analgesia in those individuals experiencing placebo analgesia but had no effect in 
those who had no placebo pain reduction. The hypothesis that placebo-induced pain reduction is 
mediated via opiate receptor mechanism is further supported by the finding that proglumide, an 
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antagonist blocking cholecystokinin-induced excitation of midbrain dopaminergic neurons, enhanced 
the placebo analgesia [73]. Similar to the inhibitory effect of naloxone on placebo analgesia, placebo 
potentiation by proglumide occurred only in placebo responders, but not in non-responders.  
 
1.3 Therapeutic Drug Monitoring 
 
Therapeutic drug monitoring (TDM) is a clinical tool that allows to measure the concentration 
of a large variety of drugs, or more generally of different bioactive molecules in human biological 
matrices such as blood, plasma and urine, but also fluids such as serum, saliva and cerebral fluid and 
cell and tissue extracts [74]. 
TDM is based on the hypothesis that there is a definable relationship between the dose of drug 
administered and its concentration in blood and/or plasma - or more generally in biological fluids - 
and between this concentration and the observed pharmacological effects. However, the correlation 
between dose and concentration of a specific drug is not always as linear as it might seem and is 
generally characterized by several variables associated with its pharmacokinetics: mode of 
absorption, distribution, metabolism, excretion, concomitant pathologies, drug-drug interactions, 
pharmacogenetics factors etc [75]. Therefore, TDM is not a simple measurement and its output is not 
a mere numerical datum, but it consists of both the accurate evaluation of the drug concentration in 
the selected matrix, and the rational interpretation of the different factors for which this concentration 
has been reached [76].  
In that light, a multidisciplinary approach is required to carry out a TDM study, and it has to 
be performed with the help of different professional orchestrating figures (doctors, pharmacists, 
nurses, biologists and chemists). This teamwork allows establishing the appropriate conclusions from 
clinical studies and optimizing therapeutic treatment, thus increasing its effectiveness and decreasing 
adverse effects [77]. 
TDM is now considered fully part of the new frontier of medicine, a personalized medicine in 
which the therapy is tailored taking in account all possible variables affecting a patient health status. 
Noteworthy, not every administrated drug is susceptible to benefit from concentration-based dosage 
adjustment in terms of improvement of therapeutic effect and/or of tolerance profile. The main criteria 
making a drug a suitable candidate to TDM are a significant inter-individual pharmacokinetic 
variability and an established relationship between blood concentrations and clinical efficacy and/or 
toxicity. TDM is generally considered for drugs that have to be administered on the long term (chronic 
conditions, e.g. new oral targeted anticancer drugs, antiviral agents against HIV infection, etc.), or 
for drugs constituting last resort treatments administered to critically ill patients, such as in intensive 
care units where appropriate exposure is key for maximizing efficacy while minimizing toxicity [78]. 
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Some of the therapeutic classes presently recognized to benefit from TDM are listed in Table 1 [74]. 
Table 1: Example of therapeutic drug classes currently subjected to TDM. 
However, there are conditions suggesting the use of TDM, regardless of the used drug. In 
particular, when clinical evidences suggest a less than expected clinical response to therapy, or if 
over-dosage is suspected in the presence of clinical signs of toxicity. Moreover, when special patients 
(pregnant, children, newborns…) are subjected to drug therapy, TDM is always advisable. For these 
populations, the available data on drug effects, toxicity and metabolism are generally reduced because 
of the limited number of treatments and/or for the lack of clinical experimentation. Therefore, there 
is an increasing occurrence of TDM use in pediatrics, also in the case of therapies involving drugs 
with a quite wide therapeutic window [79]. Analogously, TDM has to be carried out for patients 
showing a borderline pharmacogenetic profile, suggesting a possible hyper-susceptibility to specific 
drugs, when it is not possible to use a different active compound [80].  
 
1.3.1 Analytical Methods in Therapeutic Drug Monitoring  
 
Different analytical approaches have been used so far to measure the concentration of a drug 
and/or its metabolites in biologic fluids or tissues. Although approaches as Surface Enhanced Raman 
Spectroscopy [81] or electrochemical biosensors have been proposed [82], generally TDM studies 
are carried out using immunoassay-based or chromatography-based techniques. However, the 
immunoassay approach suffers from the known limitations of antibodies-based methods (high costs, 
cross-reactivity, need of a specific antibody for each analyte), and on the other hand chromatography 
coupled with UV or fluorescence detection is poorly selective, requires complex sample treatments 
Therapeutic classes Selected examples 
Immunosuppressants ciclosporin, tacrolimus, everolimus, sirolimus, mycophenolate 
Antiepileptics 
phenobarbital, phenytoin, carbamazepine, valproate, lamotrigine, topiramate, 
levetiracetam, lacosamide, zonisamide 
Anti-HIV drugs 
darunavir, atazanavir, lopinavir, efavirenz, nevirapine, rilpivirine, maraviroc, 
raltegravir, elvitegravir, dolutegravir 
Antivirals ribavirin, ganciclovir, acyclovir 
Antifungals 
voriconazole, posaconazole, itraconazole, hydroxy-itraconazole, fluconazole, 
caspofungin, aniludafungin, micafungin, flucytocin 
Antibiotics 
gentamicin, amikacin, tobramycin, vancomycin, teicoplanin, meropenem, 
imipenem, meropenem, cefepime, piperacillin/tazobactam, amoxicillin, 
flucloxacillin, ceftazidime, ceftriaxone, cefuroxime, daptomycin, ciprofloxacin, 
levofloxacin, linezolid, tigecycline 
Tuberculostatic drugs isoniazid, rifampicin, pyrazinamide, ethambutol 
Antimalarials Quinine 
Anticancer drugs 
methotrexate, busulfan, mitotane, azathioprine, mercaptopurine, thioguanine, 
imatinib, nilotinib, dasatinib, bosutinib, sunitinib, sorafenib, erlotinib, gefitinib, 
lapatinib, vemurafenib, regorafenib, tamoxifen/endoxifen. 
Antipsychotics, antidepressants 
lithium, amisulpride, asenapine, mirtazapine, iloperidone, olanzapine, 




and long analytical times, and is not always very sensitive. 
Liquid chromatography (HPLC) and gas chromatography (GC) have been considered for 
years the "gold standard", in parallel with immunometric techniques, for the measurement of specific 
substances in biological fluids such as plasma/blood and urine. Since 1960s, HPLC has gained 
popularity because of its ability to separate with exceptional resolving power and quantitatively 
analyze complex samples in a rapid and cheap manner. In recent years, the ever-increasing use of 
methods based on mass spectrometry in liquid phase (LC-MS) has opened new horizons in clinical 
analysis. However, even though LC-MS allows deep analysis with high selectivity and specificity, 
this technique requires an initial money investment for very sophisticated instrumentations which 
need skilled staff and dedicated laboratory areas.  
In the last 15 years the LC-MS/MS technology emerged for its impressive performances and 
has now became a key analytical tool for all modern clinical laboratories. High Performance and Ultra 
Performance Liquid Chromatography (HPLC and UPLC., respectively) coupled to MS/MS has 
transformed the way most drugs are now analyzed, accelerating the rate of analytical developments 
and hence playing a major role for the current deployment of TDM [83]. This technique (or better, 
this family of techniques) allows identification, structural characterization and quantitation of 
molecules that range in size from tens of daltons to hundreds of thousands of daltons. Qualitative 
analysis is based on the ability of a mass spectrometer to “weigh on the molecular scale” by 
determining the mass-to-charge ratio (m/z) of quasi-molecular-ions and fragment ions obtained by 
the ionization of the investigated compounds.  
 The LC-MS methods are characterized by a high versatility, allowing to analyze substances 
ranging from small hydrophobic molecules, to biomacromolecules, good sensitivity and a high speed 
of analysis. The high selectivity of LC-MS/MS makes it possible to simultaneously analyze many 
structurally unrelated analytes, within short times; therefore, it is possible to set-up numerous 
multiplex assays for the quantification of drugs from the same therapeutic class in a single run. Thanks 
to their sensitivity and selectivity, mass-based approaches can be easily applied to poorly purified 
samples, such as water-diluted urines.  
The setting-up of assays by MS has become greatly facilitated by the availability of stable 
isotopically-labelled Internal Standards (IS) (deuterium, 13C, 15N) that compensates for deleterious 
matrix effects variably affecting biological samples, which may otherwise compromise the accuracy 
of the analytical method. For the assay of drugs in peculiar biological matrices, such as dried blood 
spots, the use of isotopically-labelled IS assures that unidentified, possibly variable, matrix effects 
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2.1.1 Systemic Lupus Erythematosus 
The term “lupus erythematosus” was first introduced at the beginning of the 19th century to 
describe skin lesions. It took almost 100 years to understand that the disease was systemic and caused 
by an aberrant autoimmune response. Indeed, the immune system, which normally functions to 
protect against foreign invaders, is hyperactive during disease and antibodies against normal 
autologous tissues and organs are produced. Usually, immune responses are directed against skin, 
joints, kidneys, brain, heart, lungs, and blood [84]. To date, systemic lupus erythematosus (SLE) is 
defined as a chronic autoimmune syndrome characterized by a broad spectrum of clinical 
manifestations, ranging from periods of illness, or flares, to periods of wellness, or remission. Because 
of the lack of curative therapeutic strategies, early detection and treatment remain the key points for 
achieving a good clinical outcome and for reducing disease severity and the probability of 
progression.  
SLE affects individuals of all ethnical groups especially Americans, Hispanics and Africans 
with a prevalence of 20-150 cases per 100,000 population. In addition, SLE has an increased 
prevalence in women of childbearing age with a female/male ratio of 9:1 [85,86].  
Lupus is a complex disease of unknown etiology whose pathophysiology has been proposed 
to be due to a combination of genetic, environmental and hormonal factors, such as sun exposure, 
stress, some drugs and infectious agents.  
 
2.1.2 Genetics and epidemiology 
 
 Female hormones may play an important role in lupus pathogenesis given that 90% of 
patients are women. Evidence shows that menopausal women with lupus who received hormone 
therapy have a greater risk to develop flares than women who received placebo [87]. A protective 
role of male hormones has been suggested; however, in trials with dehydroepiandrosterone (DHEA) 
the presence of flares was observed only in 16% of cases [88]. Therefore, the real impact of hormones 
on lupus pathophysiology is still unclear. 
 Genetic factors might confer a predisposition in SLE development [89]. Studies have shown 
an increased incidence in monozygotic twins compared to heterozygotic twins (25 % vs 2%, 
respectively) [90,91]. Genome-wide association study (G-WAS) analysis of lupus patients and their 
relatives have highlighted several potential genetic markers involved in the pathophysiology of the 
disease. In rare cases, SLE might be related to a single gene mutation. For example, the lack of C4 or 
C1q, proteins involved in the complement system, decrease the elimination of self-reactive B cells 
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[92], or necrotic materials [93]. However, the contribution of these single-gene hits minimally affects 
the probability to develop SLE, which is instead greatly improved by increasing the number of 
predisposing factors. The analysis of SNPs has revealed the presence of SLE-associated 
polymorphisms in intronic DNA regions encoding for immune–related genes [94], such as the 
immunosuppressive cytokine IL-10, transcription factor STAT4, or TNIP1 gene encoding for the 
cellular inhibitor A20-binding protein. Several of these SNPs are also associated with other 
autoimmune diseases, such as rheumatoid arthritis or type I diabetes. [95-97]. 
 DNA accessibility to transcription factors, and thus gene expression, is regulated by DNA 
methylation and histone modifications (acetylation and methylation), regulated by various epigenetic 
factors, such as deacetylation of IL2 promoter by histone deacetylase 1 [98]. During SLE, regulatory 
regions of many lupus-related genes, such as CD40LG or CD70, are hypomethylated and 
subsequently their expression is upregulated, which may favor the hyperactivation of the immune 
system. 
 Few cases of SLE are reported to be drug-induced, the so-called drug-induced lupus (DIL); 
however, tissue and organ damage occurs similarly to SLE. Among drugs, procainamide, hydralazine, 
and quinidine are the most involved in the pathogenesis of this type of lupus. DIL symptoms are 
different from common SLE with only mild or few lupus-like symptoms, such as fever, malaise, 
weight loss, polyarticular arthralgia and symmetric myalgia. These symptoms worsen if the treatment 
is continued, otherwise a rapid resolution occurs after drug discontinuing. Therefore, this action 
provides a key (although retrospective) diagnostic tool [99]. 
 Studies have described that viruses have epitopes similar to self-antigens; for example, 
EBNA-1 protein of Epstein-Barr virus can cross-react with the self Ro antigen, a common target of 
antibodies involved in the genesis of SLE. By contrast, some endemic infectious agents (malaria and 
some parasites) could play a protective role in the development of autoimmune diseases [100,101]. 
Among environmental factors, ultraviolet radiations are well-known lupus-related factors: 
indeed, photosensitive rash is a disease classification criterion of the American College of 




 The hypothesis of a multifactorial pathophysiology of SLE is supported by the presence of 
immunological derangement in both humoral and cellular immune responses.CD4+ T lymphocytes 
have a crucial role in the pathogenesis of the disease contributing to B cell over-activation through 
an excessive production of IL-2, a key cytokine in regulation of immune cell proliferation and in 
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maintenance of self-tolerance [104]. In addition, pro-inflammatory Th17 cells by producing IL-6 and 
IL-17contribute to B cell activation and maturation in germinal centers [105].  
 In 2003, an American study performed on 130 subjects has highlighted the presence of 
specific antibodies in the blood of patients before the onset of clinical manifestations. The presence 
of different types of autoantibodies is a characteristic of SLE: antibodies against nuclear antigens 
(ANA or ANF) are the most common and react against native double or single stranded DNA (dsDNA 
or ssDNA), nucleoproteins, histones and others. Additional antibodies found in the blood of SLE 
patients are directed against cytoplasmic antigens, coagulation factors and several tissue antigens, 
such as liver or kidney. Moreover, the presence of autoantibodies is one of the main evidences of the 
autologous activation of B cells in the pathophysiology of SLE: it has been suggested that circulating 
autoantibodies are produced by B cells that lost their tolerance due to derangement of immune 
responses driven by dendritic and T cell activation [106]. 
 The formation of immune complexes by aggregation of circulating autoantibodies is 
responsible of cellular damage because of their deposition on membranes, such as glomerular 
basement membranes or capillary endothelium, leading to complement activation and cellular 
necrosis [107]. In some cases, the presence of circulating anti-RH antibodies can cause hemolytic 
anemia by humoral response against red blood cells carrying the Rh factor on their surface. Likewise, 
antibodies against coagulation factors can interfere with hemostatic functions determining bleeding 
or thrombotic events [108]. 
 
2.1.4 Clinical manifestations 
 
In early stages, clinical manifestations are non-specific and include fever, asthenia, anorexia, 
weight loss and generalized malaise. Clinical course of SLE may extremely vary based on severity 
or cycles of remission or activation, thus being a main challenge for SLE diagnosis for physicians 
[109,110]. 
The characteristic clinical feature is the “malar” or butterfly rash, an acute, erythematous and 
edematous eruption extending from nasolabial folds to the cheekbones. Other frequent skin/mucosal 
lesions are ulcers, alopecia, urticaria, Raynaud's phenomenon, purpura and acrocyanosis. However, 
these manifestations are also present in several autoimmune diseases, such as rheumatoid arthritis 
and connective tissue diseases. Musculoskeletal manifestations can occur in 90% of patients as 
symmetric inflammatory arthralgia with swelling and functional limitation of small and medium 
joints. In addition to joint involvement, myalgia and myositis often occur with non-specific muscle 
pain, sometimes associated with strength deficit and high serum concentrations of muscle enzymes. 
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Among all clinical manifestations, renal damage is a life-threating complication, and in early stage, 
damage is asymptomatic and can be accidentally discovered by routinely laboratory test. The 
presence of circulating anti-dsDNA autoantibodies and reduced levels of complement factors (C3, 
C4) can guide the differential diagnosis of Lupus nephritis. However, the goal standard for diagnosis 
remains the renal biopsy with histopathology for grading and evaluation of disease activity and / or 
the presence of irreversible damage [109-112]. Cardiovascular, enterogastric, and hepatic 
manifestations can also be observed in SLE patients. 
 
2.1.5 Clinical management 
 
To date, there are no curative therapies for SLE, even though progresses have been made in 
the management of symptoms and complications, improving both quality and life expectancy. 
Treatments are tailored based on disease severity and include non-steroidal anti-inflammatory drugs, 
HCQ, low or high doses of corticosteroids and several immunosuppressive agents (e.g. azathioprine, 
cyclophosphamide). Some selected subjects can benefit of biologic agents, such as rituximab or 
abatacept used as off-label drugs. Only in 2011, FDA approved the first biologic drug for SLE, 
Belimumab, an anti-Blys monoclonal antibodies [113]. However, HCQ represents a milestone in the 
treatment of SLE and is still recommended for prevention of flares and thromboembolic events, 
management of lipid and glucose metabolism, and to reduce tissue damage over time [114]. 
 
2.1.6 Hydroxychloroquine  
 
Antimalarial drugs with a 4‐ aminoquinoline scaffold, such as quinine, or chloroquine (CQ), 
are still essential pharmacological tools in prevention and treatment of malaria [115,116]. 
Hydroxychloroquine (HCQ), first synthesized in 1946, was proposed as a safer alternative to CQ in 
1955 [117]. Later, both CQ and HCQ were suggested as effective alternative for treatment of 
autoimmune rheumatic diseases [118]. To date, HCQ is one of the most prescribed drugs in patients 
affected by SLE. HCQ exerts its pharmacological action by preventing the occurrence of both flares 
and antiphospholipid antibody-dependent thrombotic manifestations, thus improving quality of life 
and survival of patients [114,118-121]. This drug is commonly administrated orally, as racemic 
sulfate salt, at a loading dose of 400mg/day followed by a maintenance dosage of 200–400mg/day 
[122]. Liver metabolizes HCQ into three active metabolites (Figure 3), i.e. desethylchloroquine 




DHCQ, the major metabolite, is produced through the N‐ desethylation pathway, catalyzed 
by the enzymatic activity of the cytochromes (CYP) 2D6, 3A4, 3A5 and 2C8. Previous 
pharmacokinetic studies have shown that HCQ has a long elimination half‐ life of up to 40 days. 
Hence, the onset of action after initiating the therapy is slow and the steady state may be obtained 
only after 6months of treatment [124,125]. Moreover, the efficacy of this drug is strictly related to its 
trough concentration and maintaining plasma concentration above 1000ng/mL can reduce the 
frequency of flares, as described in the PLUS study [126]. High-responder subjects usually have 
increased blood concentration of HCQ >1250 ng/mL; while low responder patients show lower 
concentrations(100-750ng/mL) [127]; and non-responders very low blood HCQ levels (0–129ng/mL) 
also related to poor adherence to therapy [128,129]. For these reasons, monitoring blood 
concentration of HCQ is highly suggested for drug dose adjustment in order to increase 
responsiveness to therapy in SLE patients. Because the fine-tuned dosage of HCQ and its metabolites 
is emerging as one of the most critical points for an effective therapy, the availability of sensitive, 
fast and inexpensive analytical methods for qualitative and quantitative measurements of these 
compounds in body fluids is required for a good clinical management of SLE. Previously published 
methodologies although valid and well-designed show several drawbacks [130-137]. First, they rarely 
evaluate HCQ major metabolites, and thus lack the ability to perform comprehensive pharmacokinetic 
studies of all active molecules deriving from HCQ metabolism. In other cases, chromatograms did 
not display an optimal separation of all species of interest. Finally, methods providing the most 
Figure 3. Molecular structure of hydroxychloroquine (HCQ) and its major metabolites: 
desethylhydroxychloroquine (DHCQ), desethylchloroquine (DCQ) and bidesethylchloroquine (BDCQ). 
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accurate results often require complex and very skilled analytical techniques (i.e. LC-MS/MS or 
sequential achiral–chiral HPLC), thus limiting their use in routinely laboratory practice.  
 
2.1.7 Project aim 
 
 An ion‐ pairing high‐ performance liquid chromatography coupled with fluorescence 
detector (HPLC‐ FL) methodology was developed and optimized to efficiently separate and quantify 
HCQ, DHCQ, BDCQ and DCQ in peripheral blood. The method was validated and used for the TDM 
of SLE patients enrolled at the Rheumatology Unit of the University “Luigi Vanvitelli” of Naples 
(Italy). The same blood samples were also analyzed using a previously validated LC-MS/MS method 
and data were compared to those obtained from our HPLC technique [133]. 
After method validation, we correlated HCQ blood concentrations to quality-of-life (QoL) in 
SLE patients. Indeed, despite increasing interest, the extent of poor adherence to HCQ treatment, its 
main originating factors and the relationship with disease progression have not been yet sufficiently 
investigated in SLE patients with prolonged inactive disease. Therefore, this study was designed in 
collaboration with the Rheumatology Unit of the University “Luigi Vanvitelli” of Naples (Italy) to 
estimate the extent of and the main demographic, clinical and laboratory factors associated with HCQ 
non-adherence, and the relationship between outcomes and HCQ blood concentration in SLE patients 




2.2 Materials and methods  
2.2.1 Patients  
 
To evaluate circulating levels of HCQ and its metabolites, patients were enrolled at the 
Rheumatology Unit of the University of Campania ‘‘Luigi Vanvitelli’’, Naples (Italy) from 
November 2014 to April 2016, after written informed consent was obtained. The study was approved 
by the Ethics Committee of the University of Campania ‘‘Luigi Vanvitelli’’. Each patient had to 
satisfy the following inclusion criteria: diagnosis according to the 2012 classification criteria of the 
Systemic Lupus International Collaborating Clinics (SLICC); complete or clinical remission (with or 
without treatment) according to the preliminary Definitions of Remission in SLE (DORIS) criteria 
for at least one year; treatment with a stable dose of oral HCQ during previous six months. If taken, 
immunosuppressants and glucocorticoids had to be prescribed at a stable dose during the previous 
month. Exclusion criteria were: concomitant fibromyalgia; psychiatric disorders; or pregnancy. 
On admission, medical history, physical examination and laboratory investigations were 
performed to assess disease activity according to the Safety of Estrogens in Lupus Erythematosus 
National Assessment SLE Disease Activity Index (SELENA-SLEDAI), and disease damage by the 
Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage 
Index of SLE. Creatinine clearance was measured based on the Modification of Diet in Renal Disease 
(MDRD). Remission was defined according to the DORIS proposal as follows: complete remission 
without treatment, i.e. absence of clinical (SLE-related) manifestations, and/or serologic 
abnormalities (low C3 and/or C4, increasing dsDNA titer), only antimalarials allowed; complete 
remission on treatment, i.e. absence of clinical manifestations and/or serologic abnormalities, therapy 
with antimalarials, prednisone 5 mg/day and/or immunosuppressants allowed; clinical remission 
without treatment, i.e. absence of clinical manifestations, presence of serologic abnormalities, only 
antimalarials allowed; clinical remission on treatment, i.e. no clinical manifestations with serologic 
abnormalities, therapy with antimalarials, prednisone 5 mg/day and/or immunosuppressants allowed. 
The following parameters were also collected: height, weight, body mass index, time of the HCQ 
tablet intake, daily dose of HCQ, smoke status (current/past smoker). In addition, each patient was 
examined to assess the co-existence of fibromyalgia according to published diagnostic criteria, and 
the concomitant use of drugs for psychiatric problems was evaluated. 
Each patient completed various tests: a visual analogue scale (VAS) for pain, fatigue and self-
assessment of disease activity ranging from 0 (none) to 100 mm (very severe/active); a VAS for 
global health (GH) status ranging from 0 (poorest) to 100 mm (the best); the Italian version of Short-
Form 36 (SF-36), summarized in two composite summary scores, the physical component summary 
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score (PCS) and the mental component summary score (MCS), ranging from 0 (poorest QoL) to 100 
(highest); the Italian version of the Health Assessment Questionnaire Disability Index (HAQ-DI) 
from 0 (no disability) to 3 (highest disability); and The Hospital Anxiety and Depression Scale for 
level of anxiety and depression, where a score of 0 to 7 for either subscale was considered to be in 
the normal range. 
Peripheral blood samples were collected to measure circulating concentrations of HCQ and 
DCQ, as described below. Treatment was prescribed according to latest published guidelines: the 
daily HCQ dose was up to 6.5 mg/kg. A follow-up visit was planned for each patient after six months 
(T6), when patients were re-assessed by clinical and laboratory testing together with a second 
peripheral blood drawing for measurement of HCQ and DCQ concentrations. The occurrence of a 
flare during the follow-up was assessed by the SELENA/SLEDAI flare composite score. Patients 
were considered non-adherent to therapy when HCQ levels were< 100 ng/ml.  
 
2.2.2  Chemicals and reagents 
 
HPLC grade water, methanol, diethyl ether and acetonitrile (ACN) were purchased from 
Romil (Waterbeach, Cambridge, UK). HCQ and its metabolites DCQ, DHCQ and BDCQ were 
obtained from LGC Standard GmbH (Milan, Italy); sodium dodecyl sulfate (SDS) and CQ were 
purchased from Sigma-Aldrich (St Louis, MO, USA). Twenty‐ five percent ammonia solution was 
obtained from Applichem (Darmstadt, Germany). 
 
2.2.3 Sample preparation 
 
Initial stock solutions of HCQ and CQ were prepared by dissolving powders in distilled water; 
DHCQ was prepared in DMSO, and DCQ and BDCQ in methanol (MeOH). Stock solution 
concentrations were 0.6 mg/mL for HCQ, 0.5 mg/mL for CQ, 10 mg/mL for DHCQ, 2.5 mg/mL for 
DCQ and 1 mg/mL for BDCQ. Working solutions were prepared by diluting stocks in HPLC-grade 
water. All solutions were stored at -20°C until use. 
Heparinized whole blood samples were collected in BD Vacutainer tubes and stored at -20°C 
until use. For optimization and validation of the analytical procedure, whole blood samples were 
obtained from healthy volunteers from the Blood Establishment of the University Hospital “San 
Giovanni di Dio e Ruggi d'Aragona” of Salerno (Italy). After optimization and validation, the 
analytical procedure was used for measurement of HCQ levels in the blood of SLE patients.  
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All blood samples were processed and analyzed in the laboratories of the Department of 
Medicine, Surgery and Dentistry “Scuola Medica Salernitana”, University of Salerno, Salerno (Italy). 
For compound extraction, 500 μL of blood were transferred to a 15 mL Falcon tube, 500 μL of water 
containing 0.13 μg/mL of CQ (used as internal standard [IS]) were added and briefly vortexed. 
Subsequently, 300 μL of 25% NH3 and 4 mL of diethyl ether were added to each sample, vortexed 
for 2 min, centrifuged at 1200 g at 4°C for 5 min, frozen and maintained at -80°C for 10 min. The 
organic layer, which remained liquid after this procedure, was then easily collected and air-dried for 
at least 14 h at room temperature. Dried residue was dissolved in 500 μL of the mobile phase and 
centrifuged at 17,000 g at 4°C for 5 min; supernatant was then transferred to appropriate vials for 
acquisition. 
 
2.2.4 Preparation of standard calibration curves and quality control samples 
 
For calibration curve, a working solution containing HCQ, DHCQ, DCQ and BDCQ, each at 
a final concentration of 10 μg/mL, was freshly prepared in water from initial stock solutions. Serial 
dilutions were then prepared to obtain concentration of 10, 25, 100, 250, 500, 1000, 1600 and 2500 
ng/mL of each analyte in a final volume of 500 μL of whole blood. Three quality controls (QC) were 
prepared by adding to whole blood from healthy volunteers the four analytes at a concentration of 




The chromatographic separation was achieved by reverse phase (RP)-HPLC using a Waters 
1525 Model Binary Pump System equipped with a multi λ fluorescence detector (model 2475), a 
photodiode array detector (model 2998) and an autosampler (model 2707; Waters, Milford, MA, 
USA). Column used was an octadecyl silane Luna C18 100 (150 × 4.6 mm, 5 μm) column 
(Phenomenex). Samples were kept at room temperature in the autosampler and column oven was set 
at 40°C. Breeze software 2.0 (Waters) was used for peak analysis, integration and linear regression 
analysis of calibration curves. A water– methanol–acetonitrile (47:10:43 v/v/v) mixture containing 
3.2 mM SDS was employed as mobile phase. The pH was adjusted to 9.4 with 25% NH3 and 25% 
orthophosphoric acid. Chromatographic separation was achieved by isocratic elution with a flow rate 
of 1.0 mL/min. Analytes were revealed using fluorescence detector; excitation and emission 
wavelengths were set respectively at 320 and 370 nm. Compounds were identified comparing their 
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retention times with available commercial standards. 
 
2.2.6 Method validation  
 
The lower limit of detection (LLOD) was defined as the lowest concentration at which the 
analytical assay can reliably differentiate the signal of the analyte peak from background noise 
(signal‐ to‐ noise ratio ≥ 3). The lower limit of quantification (LLOQ) was considered as the lowest 
concentration at which imprecision was ≤20% and accuracy was ±20% of the nominal concentration, 
based on triplicate analyses characterized by a peak intensity at least 5 times higher than baseline 
noise. 
Linearity was determined by plotting the peak area of analyte/internal standard ratio against 
the analyte concentrations; the resulting curves were fitted with a linear regression. Experimental 
concentrations were back-calculated using calibration curves to determine their deviation from the 
nominal ones. Mean standard deviation should not exceed 20% of nominal value. 
The average recovery of HCQ and its metabolites was determined by comparing the 
experimental concentration measured in three samples containing specific amounts of each analyte 
(i.e. 200, 700 and 1500 ng/mL) pre‐  and post-extraction. Pre-extraction samples were prepared by 
adding each analyte to a final volume of 500 μL of whole blood followed by extraction. Post‐
extraction samples were obtained by extracting whole blood from healthy donors and then spiking 
the amounts of analytes required to obtain the desired concentrations in processed supernatants. 
Matrix effects and possible carry-over were evaluated by analyzing samples obtained by 
extracting unspiked whole blood from healthy donors at the beginning of the analytical series, 
followed by analysis of samples containing high concentrations (700 or 1500 ng/mL) of the four 
analytes. 
Intra‐  and inter-day precision and accuracy for each analyte were evaluated at three different 
concentrations (200, 700 and 1500 ng/mL) in samples extracted from whole blood. Three replicates 
for each concentration were analyzed in the same day. An aliquot of the same samples was analyzed 
after 1 and 4 days; during this time, samples were stored at +4°C. Precision was calculated using the 
following equation, and measured by percentage coefficient of variance (CV): CV% = (standard 
deviation/mean value) ×100. Accuracy was calculated using the following equation for percentage 
of relative standard error (RSE): RSE% = [(mean - theoretical value) / theoretical value] ×100.  
Stability of stock solutions stored at −20°C was evaluated once a week for 6 months; 5 μL of 
each solution were diluted to 1 mL using HPLC‐ grade methanol and injected into the HPLC system. 
Peak areas at each timepoint were compared to those obtained at t =0. Similarly, stability of all 
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analytes in blood samples, stored at 4°C was evaluated for 5 days. 
 
2.2.7 Mass spectrometry 
 
LC-MS/MS analyses were performed using an Ultimate 3000 UHPLC coupled with a TSQ 
Endura mass spectrometer equipped by an electrospray ion source and a triple quadrupole analyzer 
(Thermo Fisher Scientific, Cambridge, MA, USA). LC-MS/MS analyses were performed using a 
previously validated method [139] with minor modifications. Briefly, compound separation was 
achieved using a Kinetex F5 column (100 × 2.0 mm, 2.6 μm; Phenomenex, Torrance, CA, USA) and 
a mixture of 0.1% formic acid in water (solution A) and 0.1% formic acid in acetonitrile (solution B) 
as mobile phase. The following gradient was used: 10% B from 0 to 1 min, linear gradient (10–37% 
B) from 1 to 3 min, 85% B from 3.5 to 5 min. Data were acquired in positive ion selected reaction 
monitoring (SRM) mode, using specific transitions for each compound: m/z 336 → 247 for HCQ, 
m/z 308 → 179 for DHCQ, m/z 292 → 179 for DCQ, m/z 264 → 179 for BDCQ and m/z 320 → 
247 for the internal standard CQ. Peak areas were measured using the Quan Browser software 
(Thermo Fisher Scientific). 
 
2.2.8 Statistical analysis 
 
Statistical analysis was performed by MedCalc software, version 12.7.0. Comparison between 
results obtained by using either HPLC or mass spectrometry was performed using the Bland–Altman 
plot [138] and the Passing–Bablok linear regression [139]. Continuous variables were analyzed by 
unpaired Student’s t-test, Mann-Whitney test, or paired t-test and Wilcoxon test, where appropriate. 
The chi-square or Fisher’s exact test was applied for categorical variables. Spearman correlation was 
used to assess relationship between [HCQ] and continuous patient-related outcome variables. P 
values <0.05 were considered statistically significant. Univariate logistic regression analysis was 
constructed to assess factors associated with HCQ non-adherence, identifying as dependent variables 
an [HCQ] < 100 ng/ml. The factors found to be significant in univariate analysis (p < 0.1) were 
included in a multivariate model. For continuous predictive variables, odds ratios (ORs) expressed 






2.3 Results and Discussion 
2.3.1 Sample preparation and extraction 
 
Great variability in HCQ blood concentrations was observed in patients treated with 
comparable doses of HCQ [140]. These variations are caused, among others, by drug binding to 
plasma proteins [131] and by HCQ internalization into erythrocytes [141]. For these reasons, whole 
blood is preferred to serum for quantification of HCQ and its metabolites for pharmacokinetic studies 
and to evaluate patient adherence to therapy [135].  
For method development and optimization, whole blood from healthy volunteers was diluted 
with an equal volume of HPLC-grade water for red blood cell lysis. Because HCQ and its metabolites 
have a basic pKa, blood was alkalized with ammonia at a final concentration (v/v) of 5.8% to increase 
the extraction yield. Several solvents and mixtures of them at various ratios have been tested for 
organic extraction, such as dichloromethane, ethyl acetate, chloroform and diethyl ether. No 
significant differences in extraction yields were described (data not shown), and diethyl ether was 
chosen as the extraction solvent because of the good extraction yield and the fastest evaporation rate. 
The freezing step was included in the extraction procedure to reduce the solubility of HCQ and its 
metabolites in the aqueous phase, and for an easy recovery of the organic phase. 
 
2.3.2 Optimization of HPLC-FL analysis 
 
A mixture of ACN–MeOH–H2O at a pH of 5.8 was initially used as mobile phase for the 
separation of standard solutions containing HCQ, its metabolites and the internal standard CQ. 
Different ratios of the three components were tested and a 47:43:10 (v/v/v) ratio was selected because 
three out of four total analytes were discriminated by HPLC-FL analysis (Figure 4A). However, HCQ 
and BDCQ seemed to co-elute in the second peak. To confirm the co-elution of the two species, an 
identical mixture lacking BDCQ was analyzed using the same method, showing a decreased intensity 
of the second peak. Moreover, peak tailing was evident for all analytes, thus negatively affecting 






Next, the pH of the mobile phase was increased to 9.4to improve resolution and sensitivity of 
the method. Indeed, HCQ and its metabolites are basic compounds and at low or neutral pH values 
or with traditional silica materials, secondary interactions might increase the interactions between the 
analyte and residual silanols, thus causing peak tailing. For this reason, by increasing the pH of the 
mobile phase, we tried to prevent charging of both silanol groups and basic compounds [142]. 
Although peak tailing appeared to be effectively reduced, HCQ and BDCQ still co-eluted (data not 
shown).  
To achieve the effective separation of HCQ and BDCQ, an ion pairing chromatography 
approach was applied [143,144], using SDS at a final concentration of 3.2 mM (0.092% w/v) in a 
mobile phase of ACN–MeOH–H2O (47:43:10), pH 9.4 [145]. Basic compounds form an electrically 
neutral ion pair with sodium alkanesulfonates such as SDS, thus positively affecting the interaction 
of poorly retained molecules with the stationary phase. The presence of SDS in the mobile phase 
allowed the discrimination of all molecules, although peak tailing was still observed (Figure 4B). 
To further improve peak shape and increase resolution, we also evaluated the influence of 
different temperatures on chromatographic elution. Column oven temperatures of 35, 40, 45 and 50°C 
were tested (Figure 5). The increase in temperature initially produced an improvement of peak shape 
and caused a reduction in the retention time of DCQ and CQ; however, exceeding 40°C worsened 
Figure 4. Presence of sodium dodecyl sulfate (SDS) in the mobile phase and corresponding effect on 
compounds separation. Chromatograms showing separation of analytes in the absence (a) or presence (b) 




analytes separation and induced a partial overlapping of HCQ and BDCQ peaks. For this reason, the 
column oven temperature was set at 40°C for further analysis. 
 
2.3.3 Method validation 
 
 The method was validated following the EMA and FDA guidelines for analytical 
procedure validation [146,147]. In particular, the following parameters were evaluated: selectivity; 
specificity; absence of carry-over; lower limit of detection (LLOD) and lower limit of quantization 
(LLOQ); linearity; matrix effect; extraction recovery; precision and accuracy; and short- and long-
term stability. 
Figure 5. Temperature influence on analytes separation and retention times. 
Chromatograms show the separation of analytes at column oven temperatures of 35°C 
(a), 40°C (b), 45 °C (c) and 50 °C (d). 
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 LLOD and LLOQ were calculated as described in Section 2.2. A LLOD of 1 ng/mL was 
observed for all analytes; the LLOQ was 15 ng/mL for DHCQ and DCQ, and 20 ng/mL for HCQ and 
BDCQ. These LLOD and LLOQ values are similar or lower than those reported in literature 
[120,134,148]. Linearity was evaluated over a concentration interval ranging from LLOD to 2500 
ng/mL for each compound (Figure 6). For each analyte, the peak area/IS ratio was plotted against the 
analyte concentrations with a 1/x weighting factor, and by fitting a linear regression. 
 
 Extraction recovery was calculated for each analyte, as described in Section 2.2, and results 
are reported in Table 2. Our data indicated that analyte recovery was slightly affected by initial 
concentration. However, it is important to note that analyte/IS ratios remained almost constant 
Figure 6. Calibration curves of HCQ and its metabolites. The ratios between peak areas measured 
for the four compounds at each concentration and the peak area measured in the same sample for the 
internal standard (CQ) were plotted as a function of the compound concentration. The coefficient of 
determination (R2) calculated for each calibration curve is reported. 
Table 2. Recovery of hydroxychloroquine (HCQ), desethylhydroxychloroquine (DHCQ), desethylchloroquine 




regardless of initial concentration (Table 3), thus resulting in a good linearity of the method over a 
wide concentration range. 
 The absence of possible contaminants and carry-over was confirmed by injecting blank 
blood samples at the beginning of each analytical series and immediately after high‐ concentration 
standards. 
 To evaluate the reproducibility of our method, we analyzed a mixture of all analytes at three 
different concentrations (200, 700 and 1500 ng/mL) over 4 days. Data reported in Table 4 show that 
our methodology allowed fora good intra- and inter-day precision and accuracy for all analyzed 
compounds. 
 Stock solution stability was also tested: a good stability for HCQ, DHCQ, DCQ, BDCQ and 
CQ was described at-20°C for more than 6 months. However, analytes in blood samples stored at 4°C 
showed a time-dependent decrease in signal intensity for all analytes, including IS. Therefore, an 
accurate and precise quantification of HCQ and its metabolites in blood could be reasonably 
performed up to the fifth day of storage at 4°C. 
 
Table 3. Metabolite/internal standard (CQ) peak areas ratio measured for HCQ, DHCQ, DCQ and BDCQ; each 
compound was analyzed at three different initial concentrations. 
Table 4. Intra- and inter-day precision (CV) and accuracy (RSE) of HCQ, DHCQ, DCQ and BDCQ, obtained at three 
different initial concentrations (200, 700 and 1500 ng/mL). SD: standard deviation. 
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2.3.4 Comparison between HPLC-FL and LC-MS/MS on a subset of clinical samples 
 
After optimization, our HPLC-FL methodology was used on a small subset of whole blood 
samples from SLE patients treated with HCQ. Each sample was processed as described above and 
analyzed by HPLC‐ FL. As already described in literature, a marked variability in the amount of 
HCQ and its metabolites was present among our cohort of treated patients (Table 5). According to 
HCQ metabolism [123], DCQ concentration was generally similar or slightly lower than that of HCQ 
in our patients, and the amount of the two less abundant metabolites (DHCQ and BDCQ) accounted 
for the 10–20% of that of HCQ. The only exceptions were patients 14 and 15, where very high HCQ 
levels were measured, and the amounts of DCQ, DHCQ and BDCQ were lower than expected. 
 
To evaluate the suitability of our approach for quantitative analysis of HCQ and its metabolites 
in clinical practice, the same samples were also analyzed by LC-MS/MS and results were compared 
to those obtained by HPLC-FL. Three concentration intervals were identified for the different species, 
corresponding to high, medium or low levels: for HCQ and DHCQ, 0–150, 151–700 and > 700 
ng/mL; for less abundant compounds, 0–50, 51–150 and > 150 ng/mL. A good accordance between 
the two analytical approaches was described for more than 90% of measured values (58 out of 64) 
(Figure 7). In addition, the Bland–Altman model was used to evaluate the accordance between results 
obtained with LC–MS/MS and HPLC‐ FL for all analytes. This analysis also showed good 
correlation for three out of the four compounds, as the resulting confidence intervals were narrow 
Table 5. Blood concentration of HCQ, DHCQ, DCQ and BDCQ measured in systemic lupus erythematosus (SLE) 
patient samples. a: peak area below the LLOQ. 
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enough (about ±10%) for HCQ, DCQ and DHCQ (Figure 8). Similar results were also obtained 
applying the Passing–Bablok linear regression model (data not shown): good correlations (R2,0.99-
0.98) were observed for HCQ, DCQ and DHCQ, whereas a less favorable correlation was described 
for BDCQ (R2 = 0.88). Noteworthy, the two methods were poorly comparable for the quantization of 
BDCQ, the less abundant metabolite. This difference might be related to the higher selectivity of LC-
MS/MS method compared with HPLC‐ FL. As a consequence, although the HPLC-FL method we 
developed and validated remain an important tool for assessing HCQ concentration in clinical routine 
settings, at this stage we decided to perform further analysis on the whole cohort of patients using the 
LC-MS/MS method, and only HCQ and DCQ concentrations were evaluated. 
 
Figure 7. Heat map comparing the concentrations of HCQ and corresponding metabolites measured by HPLC and 





2.3.5. Relationship between blood concentration of HCQ and QoL in SLE patients with inactive 
disease 
 
Clinical and therapeutic features of enrolled patients are summarized in Table 6. Ninety-five 
% of patients were female, with a mean age of 41±11 years, a median disease duration of 15 years 
(range 2–37 years), and a median SLICC damage index of 0 (range 0–3). All patients were treated 
with HCQ and 61% of these patients received additional drugs for SLE treatment. The mean dose of 
HCQ per weight was of 5.3 ±1.2 mg/kg and a mean time from last pill intake was 9.8 ±8.7 hours. 
Median [HCQ] at baseline was 327 ng/ml (range 0–4003 ng/ml), and for [DCQ] was 47 ng/ml (range 
0–650 ng/ml). There were no significant diff erences in HCQ levels between patients treated only with 
HCQ (median 285 ng/ml; range, 0–1723 ng/ml) or with additional medications (median 435 ng/ml; 
range, 0–4003 ng/ml). Similarly, no variations were described for DCQ levels between patients taking 
only HCQ (median 47 ng/ml; range, 0–239 ng/ml) or additional drugs (51 ng/ml; range 0–650 ng/ml). 
Twenty-four patients (29%) had undetectable blood [HCQ] (n = 17) or an [HCQ] < 100 ng/ml (n = 
7; mean, 67+34; range 9–99 ng/ml), reflecting a very poor adherence to therapy. Additional four 
patients showed a [HCQ] < 200 ng/ml. No patient had undetectable [DCQ], a condition suggesting a 
very recent resumption of treatment in patients with dosable HCQ. 
Figure 8. Bland–Altman plot(s) for HCQ, DHCQ, DCQ and BDCQ, obtained by plotting the average of the two 
measurements for each of the n samples (x axis) as a function of the percentage values of the differences in the 
averages (y axis). 
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The therapeutic target for reducing occurrence of SLE within six months ([HCQ] > 1000 












At baseline, median physical and mental component summary scores (PCS and MCS) were 
47 (range, 12–62) and 45 (range, 18–66), respectively. The self-reported median VAS scores were as 
follows: VAS pain 17 mm (range, 0– 100 mm); VAS fatigue 33 mm (range, 0–100 mm); VAS GH  
74 mm (range, 20–100 mm); and VAS patient self-assessment of disease activity 20 mm 
(range, 0–94 mm). The median HAQ-DI score was 0 (range, 0–2.125). All results of self-assessment 
scores are summarized in Table 7. 
 
Table 7. Patients’ related outcome measures in overall sample, in non-adherent and adherent patients. [HCQ]: whole 
blood concentration of hydroxychloroquine; PCS: Physical Component Summary score; MCS: Mental Component 
Summary score; HAQ-DI: Health Assessment Questionnaire Disability Index; VAS: visual analogue scale; mm: 
millimeter; GH: global health status. Statistically significant comparisons are in bold (p < 0.05). 
Table 6. Clinical, demographic and laboratory features of 83 patients enrolled. a: If not otherwise specified, the 
values are the number (%) of patients. [HCQ]: whole blood concentration of hydroxychloroquine; [DCQ]: whole 
blood concentration of desethylchloroquine; SLICC: Systemic Lupus International Collaborating Clinics. 
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A slight positive correlation was found between [HCQ] and both VAS pain (rho   0.275; p 
0.012) and patient self-assessment of disease activity (rho 0.267; p 0.016). A negative correlation was 
described between [HCQ] and some parameters of the SF-36, such as limitations due to physical 
problems (expressed by the domain Role limits – Physical) (rho = –0.233; p=0.04) and body pain 
(rho– 0.228; p=0.04). Since these results could be influenced by the lowest [HCQ] found in non-
adherent patients, we performed a second analysis excluding those patients; however, no significant 
correlations were observed at study entry and follow-up (data not shown). 
Poor-adherent patients reported a better QoL compared to other patients in the following 
clinical features: physical domain (median PCS, 50 vs 44, poor-adherent vs others; p = 0.021); level 
of pain (median VAS pain, 3 vs 25 mm, poor-adherent vs others; p = 0.011); reported GH (median 
VAS GH, 80 vs 67 mm, poor-adherent vs others; p = 0.043); self-assessed disease activity (median 
VAS patient, 5 vs 23 mm, poor-adherent vs others; p = 0.028); and disability (median HAQ, 0 vs 
0.625, poor-adherent vs others; p = 0.062). No significant diff erences were described between the 
two groups in fatigue, anxiety, depression or any available demographic or clinical features 
potentially influencing HCQ metabolism (HCQ dose/weight, body mass index, creatinine clearance, 
smoke). The number of non-adherent patients on concomitant immunosuppressive therapy was 
significantly higher than that of adherent patients (13/24 versus 10/59; p = 0.001); while, there was 
no diff erence in the number of glucocorticoid users (p = 0.974). At multivariate logistic analysis, the 
factors independently associated with non-adherence were the PCS (OR = 1.05; 95% confidence 
interval (CI) = 1.00–1.11; p = 0.038) and the concomitant use of immunosuppressants (OR = 4.35; 
95% CI = 1.41–13.44; p = 0.010). 
For what concerns the follow-up, of the 83 enrolled patients, 77 subjects (93%) attended the 
scheduled follow-up visit after a mean time of 7±2 months. Five of them (6%) had a minor flare (four 
skin rash; one skin rash and low platelet count); while, no major flare was observed. Occurrence of 
flare was not associated with any clinical or demographic features, reported outcome scores, low 
dsDNA positivity and/or hypocomplementemia (data not shown). Interestingly, patients who 
experienced flares had a median baseline [HCQ] of 284 ng/mL (range, 0–1723 ng/mL); while patients 
who did not flare had higher HCQ levels (median, 435 ng/mL; range, 0–4003 ng/mL) (p = 0.225). 
Fifty-four of patients on follow-up (70%) (14/20 non-adherent, 40/57 good adherent; p = 0.787) gave 
their consent to have another unscheduled blood sample to measure blood HCQ. 
Patients labelled as non-adherent at study entry achieved a significant higher [HCQ] at T6 
(median, 515 ng/mL; range, 0–1682 ng/mL) compared to baseline (median, 0 ng/mL; range, 0–99.4 
ng/mL) (p < 0.0001). Adherent patients did not show significant variations between baseline levels 
(median, 515 ng/mL; range, 0–1682 ng/mL) and follow-up (median, 631 ng/mL; range, 0–2208 





First aim of this part of this PhD project was to develop and validate a novel HPLC‐ based 
approach for qualitative and quantitative analysis of HCQ and its metabolites DHCQ, DCQ and 
BDCQ. The main strengths were the requirement of a commonly available instrumentation in clinical 
laboratories, and the complete chromatographic resolution of the four analytes. The last point was not 
trivial since HCQ and its metabolites share similar fluorometric and chromatographic properties; 
moreover, DCQ and HCQ blood levels are generally comparable in treated patients. Therefore, an 
incomplete separation between two or more peaks would seriously affect quantitative analysis. Our 
method showed linearity up to a concentration of 2500 ng/mL, which is the therapeutic range of HCQ 
and its metabolites, conferring to our method a high accuracy and sensitivity for monitoring these 
compounds in treated patients. Indeed, our method allowed an accurate estimation of a wide range of 
concentrations of all four analytes (from LLOQ up to 2500 ng/mL), both for the most represented 
(i.e. HCQ and DCQ) and for the less abundant species (i.e. BDCQ and DHCQ).  
The efficacy of our method was evaluated and confirmed by analyzing blood samples from 
treated patients; the results obtained were in clear accordance with clinical observations and were 
correlated to those obtained with more accurate techniques such as LC-MS/MS. This latter was the 
analytical approach that was used for the analysis of the whole cohort of patients. 
In the second part of this project, in fact, we investigated the prevalence of non-adherence to 
therapy in SLE patients with inactive disease by HCQ blood level measurement and by assessing 
QoL self-reported outcomes. One-third of patients with inactive disease did not take the drug 
properly; however, these patients were those with a better QoL, lower level of pain, lower self-rated 
disease activity, and in concomitant use of immunosuppressants. Flares within a six months follow-
up occurred only in patients with low blood concentration of HCQ.  
Poor adherence represents an important cause of treatment failure in patients affected by 
chronic diseases. Unfortunately, establishing the burden of non-adherence is not easy in clinical 
practice, and self-reported questionnaires are not reliable. For SLE patients on chronic HCQ, 
therapeutic HCQ monitoring can increase adherence to therapy. The rate of non-adherence assessed 
by HCQ blood measurement is highly variable (7-30%) in patients with active disease. In our study, 
a lower threshold of non-adherence was defined (i.e. [HCQ] < 100 ng/mL) in order to exclude any 
possible interference with factors known to influence HCQ blood concentration. A higher rate of 
HCQ non-adherence was described in our cohort of patients with inactive SLE; however, rates were 
similar to those reported for patients with active disease. Only 10% of patients reached the therapeutic 
target of [HCQ]> 1000 ng/ mL for reducing flare events. The number of relapses in our cohort was 
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comparable to that described by Costedoat-Chalumeau et al. (6% vs 12%), where low HCQ was the 
only predictor of SLE flares in a multivariate analysis. The discrepancy between a high rate of poor 
adherence and low numbers of flares could be explained by diff erences in concomitant treatments 
(i.e. corticosteroids, immunosuppressants) between the two cohorts, and/or by inclusion in our study 
of patients with prolonged inactive disease and, thus, less likely to relapse. However, we could only 
speculate that target blood concentration required to prevent flares in our subgroup of patients could 
be lower than 1000 ng/mL. Further larger studies with longer follow-up are required to confirm that 
lowering HCQ daily doses could effectively reduce flare rates and thus the risk of ADR such as 
retinopathy. 
In the PLUS study, no associations between HCQ blood levels and QoL were described in 
SLE patients with sub-optimal blood concentrations of the drug (100-750 ng/ml). In our study, we 
assessed HCQ levels and QoL in patients with persistent inactive disease by measuring QoL not only 
by the standard SF-36 scale, but also by taking into account other parameters, such as fatigue, pain, 
patient self-rated disease activity, anxiety and depression. Patients with fibromyalgia and psychiatric 
disorders were excluded from the study in order to avoid biases on physical and mental status of 
patients with connective tissue diseases. We found that non-adherent patients were those rating their 
disease as less active, had a lower degree of pain and a better GH perception and QoL related to 
physical problems. The perception of a better health status might lead patients to skip regularly HCQ 
intake and subsequently to non-adherence to therapy, also according to previously published studies. 
In addition, patients taking immunosuppressants were more likely to skip HCQ intake probably 
because of their belief that immunosuppressants alone were sufficient to control disease or to avoid 
potentially harmful drug overuse.  
According to previous findings, the rate of non-adherent patients decreased after enrollment 
in the study: during follow-up, only about 10% of our patients had very low HCQ levels compared to 
33% of subjects at baseline. In addition, HCQ concentrations in non-adherent patients at study entry 
reached a value comparable to those with a better adherence at their follow-up visit. Interestingly, we 
observed an improved adherence despite the unawareness of patients to a second HCQ measurement 
at follow-up. This higher adherence might be due to the mere suspicion from patients to be more 
strictly monitored, and not related to patient’s attitude to take the drug, knowledge of previous HCQ 
results or to occurrence of clinical interview. The present observation might represent an additional 
advantage of routinely measurement of HCQ blood concentration. 
Although the assessment of blood HCQ concentrations is highly specific to identify non-
adherent patients, sensitivity of the method is lower than specificity because therapeutic 
concentrations can be reached only after several days from starting drug intake. However, the 
simultaneously measurement of HCQ and DCQ could specifically identify patients who are re-
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introducing the drug just right before the follow-up visit. Indeed, DCQ is generally undetectable in 
those subjects. In our cohort, only two patients with undetectable DCQ and suboptimal HCQ blood 
levels were found. 
Limitations of our study were the short-term follow-up (six months), the small number of 
patients in the cohort, and the low number of events (flares) observed. These limitations did not allow 
us to identify clinical, serologic or reported outcomes associated with relapse, and to define a cut-off 
of HCQ blood concentration related to a lower risk of flares in patients with persistent inactive 
disease. 
In conclusion, we found that an HCQ blood concentration above the standard non-adherence 
thresholds was not associated with a lower extent of pain, fatigue, mood disorders and perceived 
disease activity in SLE patients with inactive disease. Patients who felt better and those taking 
immunosuppressants were more prone not to take HCQ properly. Our preliminary data also suggested 
that the mere suspicion of having a routinely HCQ blood measurement eff ectively improved 
treatment adherence. However, our results confirmed the utility of performing routinely blood 
monitoring of HCQ and its metabolites in clinical practice. Studies with longer follow-up will help 













Ruxolitinib monitoring in the treatment 





3.1.1 Definitions  
 
Myeloproliferative neoplasms (MPNs) or myeloproliferative disorders (MPDs) are a group of 
hematologic disorders sharing somatic mutations in signal-transduction pathways involved in 
hematopoiesis [149]. MPNs include polycythemia vera (PV), essential thrombocytosis (ET), chronic 
myelogenous leukemia (CML), and idiopathic myelofibrosis (IMF). [150]. In 2001, the World Health 
Organization, WHO has also included within the MPNs clinical entities known as Philadelphia 
chromosome negative or MPDc: chronic neuthrophilic leukemia (CNL); hypereosinophil syndrome 
(HES); chronic eosinophil leukemia (CEL); and systemic mastocytosis (SMCD) [151]. The incidence 
of MPNs is 3.5-12.6 cases per 100,000 habitants/year, with increased rates in adults and elderly.  
MPNs are usually caused by chromosomal abnormalities or somatic mutations that 
constitutively activate signaling pathways involved in cell proliferation and survival. In other cases, 
growth factors and cytokines can enhance the downstream signaling, induce the upregulation of the 
anti-apoptotic factor Bcl-XL or the activation of STAT3/5 [152-154]. The genetic hit is at the 
hematopoietic stem cell (HSC) level leading to a growth factor-independent proliferation of the 
neoplastic clone that substitute the normal hemopoiesis in the bone marrow (BM) [155]. In most cases 
of Ph-negative MPNs, a somatic G>T mutation is present at the position 1849 of exon 14 of the Janus 
Kinase 2 (JAK2) gene leading to a valine to phenylalanine substitution in codon 617 (V617F). In 5-
10% of cases, mutations can be present in genes encoding for the thrombopoietin receptor (MPL) in 
codon 515, substitution W>L/K/A, or deletions or insertions in exon 12 of JAK2. However, allele 
burden can differ among MPNs [156].  
 
3.1.2 Idiopathic Myelofibrosis 
 
IMF is a rare MPN with an incidence of 0.5-1.3 cases per 100,000 population/year, a mean 
age of onset of 60 years-old and similar incidence between males and females [157]. IMF can be 
primary or secondary to PV or TE [158]. The JAK2 V617F mutations is present in 50-60% of cases, 
and the homozygous mutation is related to a worse prognosis and the presence of cytogenetic 
abnormalities. Somatic mutations in the calreticulin gene (CALR) account for another 20-30% of 
cases; while, mutations in MPL are less frequent (7-10%). As a result, more than 10% of patients do 




Clinical manifestations are: splenomegaly; presence of myeloid and erythroid progenitor cells 
in the peripheral blood; anisopoikilocytosis, as a variance in size and shape of a red blood cell; BM 
fibrosis; and extramedullary hemopoiesis in the spleen and liver [159-161]. In early stage of disease, 
20% of patients are asymptomatic; however, complete blood counts (CBC) can show various grades 
of anemia, thrombocytosis or thrombocytopenia, and increased or decreased number of white blood 
cells. In late stage, patients show pancytopenia because of progressive BM fibrosis and hepato- and 
splenomegaly are present. In this stage, CD34+ blasts can appear in the peripheral blood and patients 
can rapidly progress to AML.  
The BM of IMF patients is characterized by increased number of stromal cells, higher levels of 
extracellular matrix (ECM) proteins and fibrin, angiogenetic and osteosclerosis factors, and also 
increased levels of cytokines, such as platelet-derived growth factor (PDGF), fibroblast growth factor 
(FGF), transforming growth factor β (TGF-β), calmodulin, interleukin 1 (IL-1) and vascular 
endothelial growth factor (VEGF) [162,163]. These cytokines are mainly produced by monocytes 
and megakaryocytes which are supposed to play a major role in IMF pathogenesis as patients show 
megakaryocytic hyperplasia with dysplasia or necrosis, and presence of circulating megakaryocytic 
precursors. These cells show an increased number of α granules in the cytoplasm and their release 
causes an increased secretion of cytokines in the BM microenvironment altering the normal 
hemopoiesis and stimulating the deposition of fibrin [164-166]. In early stage, type III collagen is the 
main component of the ECM in the BM; while in later stages, fibrotic tissue is composed by 
fibronectin, tenascin and others. Frequency of monocytes is higher in patients with IMF compared to 
healthy volunteers and circulating levels of macrophage-colony stimulating factor (M-CSF) are 
increased in the plasma of patients [167].  
There are no specific cytogenetic abnormalities for diagnosis of IMF, even though three 
alterations can be frequently found: deletion of the 13q related to a poor prognosis and increased 
frequency of AML progression [168]; deletion of the 20q; and trisomy of 1q [169]. Trisomy 8 and 
deletion of the 12p can also be detected and are related to a worse prognosis [170]. Some 
chromosomal abnormalities are also related to loss of heterozygosity (LOH) in oncogenes located on 
affected chromosomes, such as LOH of retinoblastoma-1 protein on 13q14 locus when del13q occurs 
and found in about 23% of IMF patients. However, the presence of cytogenetic abnormalities is 
always linked to a worse prognosis and a poor response to standard treatments [171].  
The number of circulating CD34+ cells is markedly increased in IMF compared to other MPNs 
and is a landmark for differential diagnosis. In addition, the number of circulating CD34+ cells 
correlates with prognosis and is a marker of myeloid metaplasia [172]. Among CD34+ cells, the most 
abundant in IMF are the megakaryocyte colony-forming units (MK-CFU); while less frequent are the 
GM-CFU, E-BFU, and GEMM-CFU.  
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3.1.3 Polycythemia Vera  
 
Polycythemia Vera (PV) is a MPN disorder characterized by: increased red blood cells and also 
often by augmented number of white blood cells and platelets; BM hyperplasia of the erythroid, 
myeloid, and megakaryocytic precursors; erythropoietin (EPO)-independent cell proliferation; and 
presence of somatic mutations in JAK2 gene, most frequently the V617F mutation (95% of cases). In 
Western countries, the incidence is 2.3-2.8 per 100,000/year and a male/female ratio of 1.2:1. In Italy, 
the prevalence is about 30 cases per 100,000 population; however, the real incidence may be higher 
because the disease may be misdiagnosed especially in elderly. The EPO-independent cell 
proliferation capacity was discovered in vitro in 1974 by Prchal et al. [173]; however, only in 2005, 
the somatic JAK2 V617F mutation was identified and linked as driven mutation in IMF pathogenesis. 
The significance of allele JAK2 burden in the pathophysiology of the disease and in the development 
of thrombotic events is still largely unknown. Patients with PV have an increased risk to develop 
AML and long-lasting PV is more likely to progress to AML [174]. In several cases, a fibrotic phase 
can precede the leukemic phase. Other negative prognostic factors are age, presence of leukocytosis, 
administration of alkylating agents in combination with hydroxyurea, pipobroman or radioactive 
phosphor [175]. 
 
3.1.4 JAK-STAT signaling pathway 
 
The Janus kinases (JAK) are a family of non-receptor tyrosine kinases that transduce the signal 
after cytokine stimulation through the JAK-STAT pathway. Molecular weight of JAK ranges from 
120 to 140 kDa and proteins have seven homology domains (JH, JAK Homology): two C-terminal 
kinase and pseudokinase JH domains (JH1 and JH2); four N-terminus FERM domain (JH4 to JH7) 
for receptor association; and the SH2 domain formed by JH3 and part of JH4 with unknown function. 
The JAK family includes four members: JAK1, JAK2, JAK3 and TYK2. This latter is usually 
associated to cytokine receptors for interferons, IL-6, or IL-10 and involved in the Th2 immune 
response. JAK1 is also linked to interferon receptors and IL-2 and IL-6 receptors. JAK2 is involved 
not only in interferon and IL-3 signaling pathways, but also in the transduction of signals from single 
chain receptors such as EPO receptor or growth hormone receptor. JAK3 is specifically expressed in 
granulocytes and is exclusively associated with IL-2 receptor.  
JAK activation is triggered by tyrosine phosphorylation in specific protein loops, which cause 
JAK dimerization on box1/box2 domains enriched in proline residues and close to cell membrane. 
Once activated, the signal is transduced by the Signal Transducers and Activator of Transcription 
(STAT) proteins. These proteins have a SRC2 (SH2) domain for dimerization, a DNA-binding 
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domain, and a trans-activation domain at the C-terminus. The STAT family includes seven members: 
STAT1, 2, 3, 4, STAT5A/B e STAT6. Various stimuli can activate JAKs inducing dimerization and 
phosphorylation through receptor binding, and then activated JAKs phosphorylate tyrosine residues 
on the cytoplasmic domains recruiting STAT proteins. After phosphorylation and dimerization, 
activated STATs translocate to the nucleus where they induce the expression of genes related to cell 
proliferation and survival or proinflammatory cytokines (Figure 9). Modifications in the JAK/STAT 
pathways are present in several autoimmune disorders and hematologic neoplasms. For example, 

















3.1.5 Ruxolitinib  
 
Ruxolitinib (Figure 10), a selective JAK1/2 inhibitor [178], has been approved in 2011 by the 
Food and Drug Administration (FDA) for the treatment of patients with intermediate or high-risk 
IMF, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential 
thrombocythemia myelofibrosis [179]. Initial approval of Ruxolitinib was based on the results of two 
phase III clinical trials: the controlled myelofibrosis study, with Oral JAK inhibitor Treatment 
(COMFORT)-I, and (COMFORT)-II [180]. All enrolled patients in COMFORT-I and II trials 
reached the primary endpoint of 24 or 48 weeks [180,181], respectively Results of these trials and of 
studies analyzing the 2- and 3-year follow-up data showed that Ruxolitinib provides significant and 
Figure 9. JAK-STAT signaling pathway in physiologic and pathologic conditions. 
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durable clinical benefits and an overall improvement in quality of life for patients with advanced IMF 
or PV [185-188]. In particular, 51.4% of treated patients experienced a reduction in spleen size >35% 
compared to baseline, In addition, patients on the Ruxolitinib arm had a greater reduction of the risk 
of death (HR=0.48; 95% IC, 0.28-0.85; p=0.009), and an increased in overall survival compared to 
those treated with standard therapies (81% vs 61%, respectively) at 144 weeks of follow-up.  
Ruxolitinib recommended starting and maintenance dose for IMF treatment depends on the 
baseline platelet count, and side effects are routinely managed through therapeutic dose adjustment 
and blood count monitoring [184,186]. However, the therapeutic efficiency and tolerability might be 
affected by the presence of genetic polymorphisms or drug–drug interactions. Furthermore, these 
drugs are administered orally and can be given over an extended period, thus occasionally leading to 
poor patient adherence [187]. As a result, patients might experience inadequate dose exposure and 
thus inefficacy of the drug; therefore, the need for a rapid and reliable method to evaluate Ruxolitinib 
concentration in biological fluids is emerging in recent years.  
 
3.1.6 Project aim 
 
Several methods have already been developed to quantify Ruxolitinib in its pharmaceutical 
forms [188] and in plasma samples [189,190] using liquid chromatography coupled to mass 
spectrometry (LC–MS/MS). This approach is associated with a considerably high sensitivity and 
specificity and remains the gold standard for simultaneous quantification of several tyrosine-kinase 
inhibitors [189,190]. However, LC–MS/MS has an high cost, requires skilled staff, and is not 
available in all clinical laboratories; therefore, high-performance liquid chromatography (HPLC) 
coupled with ultraviolet detection (HPLC–UV) or other spectroscopy detectors could be considered 
a valid and cost-saving analytical alternative [191]. For this part of my PhD thesis, we developed and 
validated a method for Ruxolitinib quantification in plasma using a reverse-phase high-performance 
liquid chromatography system equipped with a fluorometric detector (RP-HPLC-FL).   
Figure 10. Chemical structure and mode of action of Ruxolitinib. 
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3.2 Materials and methods 
3.2.1. Chemicals and reagents  
 
HPLC grade water, methanol, and acetonitrile were purchased from Romil (Waterbeach 
Cambridge, GB); ortho-phosphoric acid from Biochem Chemopharma; and dimethyl sulfoxide and 
2,3-diaminonaphthalene from Sigma-Aldrich. Ruxolitinib, obtained as a pure powder, was a kind gift 
provided by Novartis. 
 
3.2.2 Chromatography  
 
Chromatography was performed using a Waters 1525 Model Binary HPLC system equipped 
with a multiple wavelength fluorescence detector (Model 2475) and an autosampler (Model 2707). 
Samples in the autosampler were at room temperature and column oven at +30°C. Breeze 2.0 software 
was used for peak analysis, integration and for linear regression analysis of calibration curves. 
Separation was achieved using a Waters Symmetry C18 (4.6 x 75mm, 3.5µm) column, supplied with 
a Javelin column guard. A 67:33 (v/v) water:acetonitrile mixture at pH 4.8 with 25% ortho-
phosphoric acid was used as mobile phase and at a 1.0 mL/min flow rate. For analyte detection, the 
excitation and emission wavelengths of the fluorescence detector were set to 320 and 386 nm, 
respectively. 
 
3.2.3 Sample preparation 
 
Ruxolitinib and 2,3-diaminonaphthalene (used as internal standard; ISTD) stock solutions 
were prepared by dissolving commercial powders in dimethyl sulfoxide at concentrations of 5 mg/mL 
and 1.2 mg/ mL, respectively. Stock solutions were diluted in 100% methanol for Ruxolitinib and in 
HPLC grade water for ISTD in order to obtain working solutions. All solutions were stored at -20°C 
until use.  
Ethylenediaminetetraacetic acid (EDTA) blood samples were collected from healthy 
volunteers recruited at the Blood Bank of the University Hospital “San Giovanni di Dio e Ruggi 
d’Aragona” in Salerno (Italy) in accordance with the Declaration of Helsinki. For plasma collection, 
whole blood samples were centrifuged at 3,500g for 6 min, then plasma collected into a clean safe-
lock tube and immediately stored at –20°C until use. Before extraction, 5 μL of a 2 μg/mL solution 
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of ISTD was added to 100 μL of each sample; this mixture was then added to 400 μL of 100% 
methanol directly on a vortex in a safe-lock 1.5 mL tube. After vortexing for 20 seconds, samples 
were centrifuged at 17,000g at 4°C for 10min. The organic layer was then collected, dried with a 
Savant Speed-Vac Concentrator (ThermoFisher), and dried residue was dissolved in 100 μL of 50% 
acetonitrile. After centrifugation at 17,000g at 4°C for 1min, supernatants were transferred to 
appropriate tubes for acquisition.  
For calibration curve preparation, a working solution containing Ruxolitinib at a final 
concentration of 25 μg/mL was freshly prepared in water from the initial stock. Serial dilutions (500, 
250, 100, 20, 1, 0.5, and 0.2ng/mL) were carried out in a final plasma volume of 100 μL in which 5 
μL of ISTD at 2 μg/mL) were added. Molecules were then extracted according to the procedure 
described above. Quality controls (QCs) at concentrations of 100, 20, and 0.5 ng/mL were prepared 
using the same procedure. 
 
3.2.4 Detection and quantification limits 
 
LLOD and LLOQ were defined as detailed in Section 2.2.6. Briefly, the lower limit of 
detection (LLOD) was defined as the lowest concentration at which the analytical assay allowed to 
reliably differentiate the signal of the analyte peak (S) from background noise (N) (S/N>3). The 
LLOQ was considered as the lowest concentration at which precision and accuracy were within 20% 
and a S/N>5. To perform these measurements, samples were prepared at concentrations of 0.05, 0.1, 
and 0.2 ng/mL and analyzed in triplicates.  
 
3.2.5 Linearity and recovery 
 
Linearity was determined by plotting peak area of analyte/IS ratios as a function of analyte 
concentration and fitting the curve to a linear regression. Experimental concentrations were back-
calculated using the calibration curve to evaluate their deviation from nominal values. The average 
recovery of Ruxolitinib from plasma was determined by comparing experimental concentrations from 
three samples subjected to pre- and post-extraction processing. Pre-extraction samples were obtained 
by directly adding Ruxolitinib at 0.5, 20, and 250 ng/mL concentrations to a final volume of 100 μL 
of blank plasma. These samples were then processed as described above. The post-extraction samples 
were prepared by spiking in an extracted blank plasma the quantity of compound required to obtain 
the same concentrations of pre-extraction samples. 
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3.2.6 Intra- and inter-day variability  
 
Intra- and inter-day precision and accuracy were evaluated at three different concentrations 
(0.5, 5 and 40 ng/mL) in samples extracted from plasma. Three replicates for each concentration were 
extracted and analyzed in the same day; aliquots of the same samples were extracted and analyzed 
three times per run after 1 and 3 days. Samples were stored at -20°C until analysis. To evaluate 
precision, the coefficient of variations (%CV) was calculated, and accuracy by relative error (%RE) 
between nominal and measured concentrations. 
 
3.2.7 Stock solutions and sample stability  
 
Stock solutions of Ruxolitinib and ISTD were stable for more than six months at -20°C. 
Analyte stability in plasma samples was evaluated on three independent aliquots at three nominal 
concentrations. The short- (24h) and long-term (15 days) stability in plasma was assessed at +4°C, -
20°C and/or room temperature. The stability of the extract after 48h at +4°C (temperature at which 
autosamplers usually operate) and following three freeze/thaw cycles was also evaluated. A sample 
was considered stable if the average of concentrations measured in each set of experiments was within 
±15% of the concentration initially determined. 
 
3.2.8 Method robustness  
 
Robustness of our method was evaluated by introducing minimal voluntary according to the 
model proposed by Savic et al. [192,193]. The standard flow rate of 1.0 mL/min was changed by 
±0.2mL/min, maintaining the other components of the mobile phase unaltered. The influence of 
column temperature was evaluated at 30°C, 35°C, and 40°C. Each experiment was performed in 
triplicate. Data analysis was carried out using a linear regression by a second-order polynomial model, 
in which flow and temperature were the variables. The number of theoretical plates, to evaluate 




3.3 Results and discussion 
3.3.1 Optimization of chromatographic conditions 
 
An HPLC-FL method suitable for the detection and quantization of Ruxolitinib in human 
plasma should be highly selective and sensitive for the target molecule. For this reason, excitation 
and emission wavelengths were carefully evaluated, and the 320 nm excitation/386 nm emission pair 
was selected for both the analyte and the internal standard because the highest signal intensity for 
Ruxolitinib was obtained using these parameters (Figure 11).  
 
Method efficacy strongly depends on the quality of chromatographic separation, which is 
determined by composition of the mobile phase. Initially, a ternary mixture of 
acetonitrile:methanol:H2O (50:40:10), pH 2.9 with 0.001% trifluoroacetic acid (TFA) was used; 
however, Ruxolitinib retention time was too low (less than 1.00 min). An increase of pH value to 4.8 
slightly improved retention time to approximately 1.2 min. Therefore, a mobile phase of 60:40 
H2O:acetonitrile at pH 4.8 was then used, giving a good separation between Ruxolitinib and other 
plasma peaks, but the compound partially co-eluted with the IS, as shown in Figure 12A. Different 
component ratios were tested, and the best results were obtained with a mobile phase composed of 
67:33 H2O:acetonitrile at pH 4.8, which provided a good separation of all peaks and an overall short 
run time (5.00 min) (Figure 12B,C). 
 
Figure 11. Selection of optimal fluorimeter wavelengths. The chromatogram shows the intensity obtained for 
Ruxolitinib with (A) excitation at 320nm and emission at 386nm compared to (B) excitation at 330nm and emission 





3.3.2 Pre-analytical treatment 
 
The good selectivity achieved using the HPLC-FL method described above allowed the set-
up of a simple pre-analytical treatment of plasma samples involving a methanol induced protein 
precipitation followed by air-drying and suspension in a suitable solvent. Various solvents were 
evaluated in order to identify the most effective suspension system. A 50:50 H2O:acetonitrile mixture 
provided a satisfactory yield and extraction recovery for both the analyte and the ISTD (Table 8). 
 
3.3.3 Method validation  
 
Our analytical procedure was validated according to the EMA guidelines 
(EMEA/CHMP/EWP/192217/2009 Rev. Corr. 2). No interferences from endogenous compounds 
were observed in either of the investigated biological fluids (data not shown). The injection of highly 
Figure 12.  Mobile phase optimization. Chromatograms show the improvement in the separation of analytes peaks: 
(1) unspecific plasma residue, (2) internal standard, and (3) Ruxolitinib. Different water:acetonitrile ratios were 
evaluated in the mobile phase at pH 4.8: (A) 40:60, (B) 50:50, and (C) 67:33. A flow rate of 1.0ml/min was used in 
all experiments. 
Table 8. Recovery after organic extraction for Ruxolitinib and 2,3-diaminonaphthalene calculated at three different 
initial concentration values. 
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concentrated samples (up to 1 μg/mL) followed by the analysis of blank samples did not show the 
presence of carry-over (Figure 13). Injection of blank blood samples was also performed at the 
beginning of each analytical series and immediately after high‐ concentration standards. 
 
The LLOD for Ruxolitinib in plasma was 0.05 ng/mL, and the LLOQ was 0.1ng/mL. The 
linearity was verified over a concentration range from 0.2 ng/mL to 500 ng/mL (n = 7) (Figure 14); 
correlation coefficient obtained (R2 = 0.9994) confirmed the suitability of this analytical approach to 
measure a wide range of drug plasma concentrations. Accuracy and precision of the analytical were 
estimated intra- and inter-daily using plasma samples from healthy volunteers at three different 
Ruxolitinib concentrations (0.5, 5, and 40 ng/mL) across a linear range (Figure 14). As shown in 
Table 9, CVs were <15% and relative errors (RE) < ±10%, confirming the reproducibility of our 
method. Analyte stability in plasma was evaluated d as described in the Materials and Methods 
section on three independent aliquots at three Ruxolitinib nominal concentrations, i.e. 0.3, 40, and 
400 ng/mL, which corresponded, respectively, to three times the LLOQ, the middle part of the 
linearity range, and a value closer to the upper limit of the calibration curve.  
 
Table 9. Intra-/Inter-day precision and accuracy expressed, respectively, as the coefficient of variation and 
the relative error obtained for Ruxolitinib. 
Figure 13. Potential carry-over among samples evaluated by loading a blank sample following the 




Plasma samples were stable at different temperatures and for different storage periods (Table 
10), as CVs were within ±15%. Conversely, extracted samples did not satisfy this requirement, 
probably because the IS might be less stable than Ruxolitinib both in the stored and in the 
frozen/thawed extracted samples (data not shown). Therefore, samples should be preferably extracted 
right before the analytical session. The robustness tests highlighted that flow rate might influence 
chromatographic efficiency more than temperature values, as shown by variations in the number of 
theoretical plates (Figure 15). However, chromatographic efficiency remains satisfactory even after 
flow rate or temperature modifications, and those minimal variations did not significantly affect 





Table 10. Ruxolitinib stability at 0.3, 40, and 400ng/mL evaluated in plasma samples at different temperatures 
and time intervals. 
Figure 14. Linearity of the analytical response determined by plotting the ratio of Ruxolitinib peak area/2,3-
diaminonaphthalene peak area as a function of Ruxolitinib concentration, and fitting the curve by linear 





Figure 15. Robustness analysis. Number of theoretical plates plotted as a function of the flowrate values 0.8, 
1, 1.2mL/min at different temperatures: light gray, 30°C; gray, 35°C; dark gray, 40°C. 
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3.4 Conclusions  
 
The measurement of the effective plasma concentration of a specific drug plays a pivotal role 
in assisting the clinician in the decision-making process of keeping the current treatment by adjusting 
drug dosage or changing the type of drug molecule administered to the patient. This is particularly 
critical in case of treatment failure, severe side-effects, or suspected drug interactions.  
JAK inhibitors therapeutic efficacy is known to be affected by a marked variability; therefore, 
regular monitoring of these compounds is required to ensure both an optimal response and the 
reduction of potential adverse effects. The correlation between therapeutic efficacy and plasma 
concentration has been widely studied for this class of molecules [195-198]. Nonetheless, an ongoing 
debate concerning the thresholds for other tyrosine-kinase inhibitor is still under way, as the existing 
studies are contradictory [199]. Therefore, further work concerning therapeutic monitoring of these 
drugs is strongly encouraged. The purpose of this paper was to optimize and validate a simple HPLC-
FL method to measure Ruxolitinib concentration in plasma samples, even at low concentrations. The 
method was developed taking into account the chemical and physical properties of the drug; in fact, 
the low polarity (LogP of 2.1) of Ruxolitinib allowed the molecule to be analyzed by reverse phase 
liquid chromatography. The mobile phase composition was optimized to obtain two symmetric peaks 
(Ruxolitinib and internal standard) with a short time run. The coefficient of variation and relative 
error values for precision and accuracy studies and the high recovery rate of Ruxolitinib indicate that 
the proposed method is valid. There is no evidence of additional peaks that can interfere with 
Ruxolitinib or the internal standard, nor are there any interference peaks in extracted plasma samples. 
In conclusion, the feasibility and linearity of the results in plasma samples strongly support a 
widespread diffusion of this analytical method for the quantification of Ruxolitinib in 







5-Fluorouracil monitoring of oncologic 





4.1.1 TDM applied to chemotherapeutic agents 
 
Therapeutic Drug Monitoring (TDM) is used for dose adjustment of drugs with narrow 
therapeutic windows, such as chemotherapeutic agents with step dose–response relationship, in order 
to reduce toxicities, improve effects on targeted tissue and increased drug availability. In addition, 
TDM can decrease adverse drug reaction (ADR)-related morbidity, while increasing therapy efficacy 
and reducing costs for treatment of ADRs [200,201]. Anticancer drugs have also a significant inter-
individual pharmacokinetic variability; for example, drug clearance is expressed as function of body 
surface area (L / h / m2) or subject weight (L / h). In addition, the presence of polymorphisms, somatic 
mutations or other modifications that could influence pharmacokinetics is also responsible of inter-
individual variability. Activity of anticancer drugs is mirrored by the area under the plasma 
concentration curve (AUC) versus time, which is reached in one or two days after a short intravenous 
infusion and before neutrophil and platelet counts at the nadir (lowest values) observed 1-2 weeks 
after chemotherapy. All of these characteristics make TDM suitable for measurement of anticancer 




5-FU, an uracil analogue where the hydrogen atom at the C5 position is substituted by a 
fluorine atom (Figure 16), is widely used in combination with other anticancer drugs for the treatment 
of several solid malignancies, such as colorectal, head and neck and breast cancers [203]. 
 
The effects of 5-FU on response rates and patient survival is well established. Nevertheless, 
only 10-15% of patients with advanced colorectal cancer respond effectively to treatment [204]. The 
combined use of 5-FU with new CA such as irinotecan and oxaliplatin improved the response rates 
of advanced colorectal cancer of 40 to 50% [205,206]. 5-FU can rapidly enter into cells by facilitated 
Figure 16. Chemical structure of 5-Fluorouracil. 
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or passive transport mechanism [207,208] where it is converted into several active metabolites such 
as fluorodeoxyuridine monophosphate (FdUMP), fluorodeoxyuridine triphosphate (FdUTP) and 
fluorouridine triphosphate (FUTP). These metabolites and not the 5-FU are responsible of the 
cytotoxic effects of the drug through DNA and RNA damage (Figure 17). Indeed, 5-FU metabolites 
are incorporated into macromolecules, such as DNA and RNA blocking gene and protein expression 
and DNA replication mechanisms.  
 
The intracellular availability of 5-FU mainly depends on tissue catabolism: more than 80% of 
a single dose of 5-FU undergoes metabolic clearance [210] in the liver through the activity of the 
dihydropyrimidine dehydrogenase (DPD) enzyme [211]. DPD, an enzyme that catalyzes the rate-
limiting step in fluorouracil metabolism, is encoded by the DPYD gene. In eukaryotic cells, in the 
first step of pyrimidine catabolism, the DPD enzyme reduces 5-FU to 5-fluoro-5,6-dihydrouracil (5-
DHFU) that is rapidly converted by the dihydropyrimidinase to 5-fluoro-ureidopropionic acid 
(FUPA), and then to α-fluor-β-alanine (FBAL; the major urinary metabolite) by the β-
ureidopropionase (Figure 18) [212]. 
 




4.1.3 -Therapeutic drug monitoring of 5-Fluorouracil 
 
Pharmacokinetic variability of 5-FU depends on various factors such as age, gender, disease 
status, organ functions, drug-drug interactions, and also the activity status of the DPD enzyme [214]. 
Almost 5% of patients have DPD deficiency that causes 39-61% of all 5-FU-related severe toxicities 
[215]. Screening for DPYD gene variations can discover polymorphisms related to DPD deficiency 
and dramatically reduce 5-FU ADRs. More than 30 variants in the DPYD gene are annotated so far; 
however, only two polymorphisms are related to loss of function in DPD enzyme: DPYD*2A and 
DPYD*13 [216]. The DPYD*2A variant at the spiking site between intron and exon 14 causes the 
production of a truncated protein, and in homozygosity there is a complete DPD deficiency which 
might expose patients to potentially life-threatening toxicities, such as bone marrow suppression and 
neurotoxicity [217]. In heterozygosity, the Clinical Pharmacogenetics Implementation Consortium 
set up a 5-FU dosage based on DPYD genotyping [218]. However, around 50% of patients treated 
with 5-FU experience various grade and type of toxicity without genotypic alterations in the DPYD 
gene, suggesting that other factors are implicated in the development of 5-FU-related ADRs [216]. 
Indeed, DPD expression is also regulated at the transcriptional and post-transcriptional levels [219]. 
For this reason, a correlation between genotyping and phenotyping is required to better evaluate 
enzymatic DPD activity before starting 5-FU treatment. One approach consists of plasma 
measurement of 5-FU concentrations; however, other strategies are under investigation, such as the 
evaluation of DHU/U ratio or uracil concentration measurement. The use of these markers is still 
limited in clinical practice because of the lack of validation studies on large cohorts [219-224]. 
 
4.1.4 Project aim 
 
In order to increase the tolerable dose of 5-FU while minimizing drug-related toxicities, 
several strategies have been introduced in chemotherapeutic protocols, such as the addition of 
Figure 18. Metabolic breakdown of 5-FU [213] 
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leucovorin, a vitamin B9 derivative, or continuous intravenous infusion [216,225,226]. However, 
severe ADRs are still observed in 10-30% of patients without DPD deficiency treated with 
fluoropyrimidine monotherapy with a death rate of 0.5-1% [215,219,227]. This mortality rate is even 
higher when 5-FU is associated to other chemotherapeutic agents, such as irinotecan and oxaliplatin 
[228]. Therefore, the use of TDM have a relevant impact in clinical management of oncologic patients 
treated with 5-FU as monotherapy or in combination with other anticancer drugs. For this reason, we 
developed and optimized a LC-MS/MS method for quantization of 5-FU in plasma samples later 




4.2 Materials and methods 
4.2.1 Patients 
 
Patients included in this study were enrolled at the Oncology Unit of the University Hospital 
“San Giovanni di Dio Ruggi d’Aragona”. Salerno (Italy). and ethylenediaminetetraacetic acid 
(EDTA) or heparinized blood samples were obtained after written informed consent was obtained. 
After centrifugation at 3.500g for 6 min. plasma was collected into a clean safe-lock tube and 
immediately stored at -20°C and processed within 48h.  
 
4.2.2 Chemicals and reagents  
 
UHPLC grade water. methanol. and acetonitrile were purchased from Romil (Waterbeach 
Cambridge. GB); dimethyl sulfoxide (DMSO). 5-FU. thiobarbituric acid (TBA) HRX and Phree 
column from Sigma-Aldrich.  
 
4.2.3 Solution preparation 
 
To obtain stock solution, 5-FU and TBA (used as internal standard; IS) powders were 
dissolved in DMSO to a final concentration of 1 mg/ml; work solutions were then obtained by diluting 
stocks in H2O. All solutions were stored at -20° C. 
 
4.2.4 5-FU extraction  
 
For 5-FU extraction from plasma samples. 2 µL of IS solution at a concentration of 10 µg/mL 
were added to 198 µL of plasma (final concentration. 100 ng/mL). sample was vortexed and 
centrifuged at 13000 rpm for 2 min. Subsequently. 50 µL of supernatant were collected into a clean 
safe-lock tube and 200 µL of methanol were added while vortexing the sample. After 30 min 
incubation at RT with vortex step every 10 min. samples were subjected to centrifugation at 4°C at 
17000g for 5 min; then 200 µL of supernatant were collected into a clean safe-lock and dried using a 
vacuum centrifuge for 50 min at 45°C. Pellets were dissolved in 40 µL of 5% methanol solution. 
vortexed and centrifuged at +4°C at 17000g for 1 min. Clear supernatants were then transferred in 
appropriate vials for LC-MS/MS analysis.  
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4.2.5 Preparation of calibration standards and quality controls  
 
For calibration standards. a 5-FU solution at 500 µg/mL was freshly prepared in H2O from 
stock solutions and serial dilutions (10. 1. 0.1 and 0.01 µg/mL) prepared in a final plasma volume of 
500 µL. The range of concentrations was selected based on our LLOQ value and data previously 
reported in literature. Samples were then extracted according to the procedure described above. 
 
4.2.6 LC-MS/MS analysis 
 
LC–MS/MS analysis was carried out using an Ultimate 3000 UHPLC system (Thermo-Fisher. 
Waltham. MA. USA) coupled with a TSQ endure mass spectrometer (Thermo-Fisher) equipped with 
an electrospray ion source and a triple quadrupole ion analyzer. 
Chromatography was performed by injecting 5 µL of samples on a Phenomenex Luna Omega C18 
(2.1 x 50 mm. 1.6 μm) and a mobile phase composed of 0.1% formic acid in water (A) and 0.1 % 
formic acid in acetonitrile (B). An elution gradient from 2% to 30 % of B over 3 min at 20°C at flow 
rate of 0.4 mL/min was used for compound separation. 
Mass spectra were acquired in negative multiple reaction monitoring (MRM) 
mode. Specific transitions (Figure 19) were selected by direct injection for each analyte in order to 
maximize selectivity and sensitivity: 5-FU transitions 129→86 and 129→59; and IS 143→75. Peak 













Figure 19. 5-FU fragmentation. 
62 
 
4.2.7 Method validation 
 
LLOD and LLOQ were defined as described in paragraph 2.2.6, and, to this purpose. samples 
were prepared at various concentrations and analyzed in triplicates.  
Linearity was determined by plotting peak area of analyte/IS ratios as function of the analyte 
concentration and by fitting the curve to a linear regression. Experimental concentrations were back-
calculated using calibration curves to determine their deviation from nominal values. 
Intra-day and inter-day precision and accuracy were evaluated at two different concentrations (0.1 
and 1 µg/mL) in samples extracted from plasma. Five replicates for each concentration were extracted 
and analyzed three times per run. Then aliquots of the same sample were stored at +4°C and analyzed 
again (three times per day) after 24 (T24). 48 (T48) and 96 (T96) hours. Percent coefficient of 
variance (% CV) for each measurement was calculated to assess precision. and the percent of relative 





4.3 Results and discussion 
 
Therapeutic Drug Monitoring of drugs with narrow therapeutic windows and higher inter-
individual variability is mandatory to better tailor therapy on patients maximizing drug effectiveness 
while minimizing toxicities. In this part of my PhD thesis, we developed and optimized an analytical 
method for 5-FU measurement in plasma samples. This molecule is extremely unstable in whole 
blood and plasma at room temperature because of rapid degradation to dihydro-5-FU by the 
ubiquitarian dihydropyrimidine dehydrogenase enzyme (DPD). For this reason, blood samples should 
be kept on ice and plasma collected within few hours from drawing [229]. In addition, DPD inhibitors 
might be added to blood collection tubes in order to increase 5-FU stability. Noteworthy, an incorrect 
storage and manipulation could lead to a rapid 5-FU degradation thus leading to under-estimation of 
circulating drug levels and inappropriate drug dose adjustment.  
Several analytical methods have been developed for measurement of 5-FU and its related 
compounds [230] by high-performance liquid chromatography (HPLC) using standard. reverse phase. 
or reverse-phase ion pairing techniques. Therapeutic ranges that can be defined using these 
methodologies are usually between 25-150 ng / ml (0.19-1.15 μM). However, by employing liquid 
chromatography coupled with mass spectrometry (LC-MS/MS) analysis limits of quantization have 
been lowered to 0.5 ng/mL (3.85 nM) or 10 ng/mL (0.08 μM) improving sensibility and specificity 
of 5-FU measurement and minimizing sample volume needed (100 μL of starting plasma sample 
volume) [216]. 
We developed and optimized a highly sensitive, specific and accurate analytical method for 
measurement of 5-FU and its related compounds in plasma samples by LC-MS/MS. The method was 
also validated in a cohort of patients with various types of cancers such as colon head & neck or 
breast neoplasms receiving 5-FU alone or combined with other anticancer drugs as their therapeutic 
protocol. Measurement of circulating levels of 5-FU and its metabolites could be used as additional 
tool in dose adjustment in patients treated with chemotherapeutic agents. However. polymorphisms 
in DPD, type of cancer, co-morbidities and concomitant use of other medications should be also 
considered for a better clinical management of oncologic patients.  
First, selectivity was assessed by analyzing samples without 5-FU and ISTD but with other 
commonly used drugs. Based on the EMA guidelines the absence of interfering molecules is accepted 
when the signal at the same retention time of the target drug is less than 20% of the LLOQ for the 
analyte and less than 5% for the ISTD. For 5-FU and ISTD used in our method there were no 
interfering compounds. Specificity was evaluated based on the consistency of the retention time for 
a certain analyte across runs and the presence of both products (quantifier and qualifier) in a constant 
ratio for a precursor (Table 11). Our method showed high specificity for each analyte.  
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Next, various extraction procedures were tested in order to develop a methodology characterized 
by the highest extraction recovery. Injection of whole blood samples or plasma is not suitable in LC-
MS/MS because lipids, proteins and salts can damage the instrumentation and also interfere in the 
measurement of targeted molecules. For this reason, a sample clean-up is required; however, 
compounds of interest do not need to be removed together with interferes. Plasma proteins were 
precipitated in acetonitrile (1:3. v/v); recovery was not satisfactory with this method (data not shown). 
A solid phase extraction was then performed using HR-X (Chromabond) or Phree (Phenomenex) 
columns (Table 12). In Phree columns, lipids and proteins strongly interact with the stationary phase 
and 5-FU, a highly hydrophilic molecule, can be eluted from columns. Using HR-X columns, the 
analyte first interacts with the stationary phase and is subsequently eluted using appropriate solvents. 
Using solid phase extraction, 5-FU (0.2 or 2 ng/mL) and IS were rapidly eluted and the extraction 
Molecule Retention time Transition I Transition II II/I ratio (%) 
5-FU 0.43 min 129-42 129-86 13-17 % 
ATB 0.38 min 143-75   
Figure 20. Chromatograms of 5-FU and IS by LC-MS/MS. 
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yield was low: for Phree columns, extraction was <40% for 5-FU and 20% for IS; for HR-X columns, 






Table 12. 5-FU and IS extraction rates using various procedures (methanol, MeOH; and solid phase extraction, Phree and 
HR-X).  
  
Finally, an extraction procedure using methanol was employed in a sample/solvent ratio of 
1:4 (v/v). Using this method, extraction rate for 5-FU at 0.2 ng/mL was 65% and at 2 ng/mL was of 
70%; while the IS extraction rate was 56%. Methanol extraction showed the best recovery rate and 
the procedure was employed for further analysis (Figure 20 for chromatograms).  
As first step for method validation, LLOD and LLOQ were defined according to the EMA 
guidelines. In our case, LLOQ was identified at 10 ng/mL, which was considered appropriate for our 
aim because our LLOQ was much lower than reported lower limits of 5-FU therapeutic window. 
Linearity was then assessed according to ranges reported in literature. In particular, 5-FU plasma 
levels at the steady-state should be between 2500-3000 ng/mL; lower or higher concentrations require 
dose adjustment as reported in Table 13. However, by LC-MS/MS analysis, a narrower window is 




 MeOH Phree HRX 
5FU (0.2) 64±5 32±4 16±7 
5FU (2) 69±3 38±9 18±5 
















Table13. Dose adjustment based on 5-FU plasma levels.  
 
Based on literature, we assessed linearity of our method using concentrations between 10 ng/mL and 


















AUC 5-FU Dose Adjustment 
(mg×h×L-1) (± % of previous dose) 
< 500 <4 70 
500-1000 4 to < 8 50 
1000-1200 8 to < 10 40 
1200-1500 10 to < 12 30 
1500-1800 12 to < 15 20 
1800-2200 15 to < 18 10 
2200-2500 18 to < 20 5 
2500-3000 20 to < 24 Unchanged 
3000-3500 24 to < 28 -5 
3500-3700 28 to < 31 -10 
>3700 > 31 -15 
Figure 21. Range of linearity.  
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Precision and accuracy were evaluated as described above. In details, %CV values were <5% 
for all inter-day and intra-day quality controls, and %RSE were <3% for all samples, except for the 
intra-day quality control at 2µg/mL (Table 14). However, values were lower than the accepted cut-
off of 15%, confirming that our method was precise and accurate. In addition, samples stored at +4°C 
showed a good stability. 
Concentrations INTRADAY INTERDAY 
ng/mL % CV % RSE % CV % RSE 
0.2 3.5 2.9 4.1 1.1 
2 1.0 5.9 3.9 0.9 
10 4.4 2.3 4.9 2.0 
Table 14. Intra- and inter-day precision (CV %) and accuracy (RSE %). 
 
For validation in a cohort of oncologic patients, blood drawings for TDM were performed at 
time 0 before 5-FU infusion; 3 to 18 min after the rapid injection; and 45 and 120 min after starting 
the infusion. Pharmacokinetic studies proposed that the steady-state is reached after 2 hours from the 
infusion; however, in our cases, we decided to consider 45 min as steady-state in order to collect 
blood for all patients who usually left the hospital setting after therapy. All patients had 5-FU levels 
lower than LLOQ before infusion (Table 15), confirming the drug is rapidly metabolized within 
cycles of chemotherapy. Values were highly variable at the rapid injection time ranging from 6,211 
to 25,765 ng/mL. Drug concentrations were increasingly higher at 45 min and 2 h in patients without 
or with polymorphisms in the DPYD gene related to 5-FU metabolism. In particular, patients with 
DPYD polymorphism had higher 5-FU plasma concentrations at the steady-state suggesting 
alterations in drug metabolism between cycles (Table 16 and Figure 22). For patient B.N., 5-FU dose 
was reduced after the first cycle and drug levels were already undetectable at the beginning of the 
third cycle. In this case, TDM allowed tailoring therapy on patient B.N. reducing 5-FU toxicity due 
to higher plasma levels. Patient A.F. carrying a DPYD polymorphism showed higher 5-FU plasma 
levels even though drug dose was reduced already at the second cycle. This patient experienced severe 































Table16. Patients carrying DPYD polymorphisms and their corresponding 5-FU plasma levels at each cycle of 






Patient Polymorphism T0 
Rapid 
(ng/mL) 
T45 min 2 h 
(ng/mL) (ng/mL) 
F.G. NO 0 9740 416 320 
P.F. NO 0 6758 332 152 
M.C. NO 0 14862 409 280 
C.A. NO 0 10150 385 220 
S.L. 1 NO 0 9103 415 228 
F.G. NO 0 12313 535 323 
S.L. 2 NO 0 8962 377 175 
C. NO 0 13975 469 386 
B.N.1 DPYD*2A 0 12091 950 615 
B.N.2 DPYD*2A 0 9340 392 183 
V.P.1 DPYD*2A 0 10861 474 224 
A.F.1 DPYD*2A 0 6211 811 X 
B.N.3 DPYD*2A 0 25765 X X 
V.P.2 DPYD*2A 0 6624 342 X 
A.F.2 DPYD*2A 0 9682 1093 X 
A.F.3 DPYD*2A 0 6780 372 X 
Patient 
Cycles of chemotherapy 
1 2 3 4 5 
B.N. 950* 392    
V.P.  474 342 372  




































Neonatal monitoring of phenobarbital 




5.1.1. Neonatal TDM 
 
Human body is in a continuous change and neonates differ from children to teens to adults 
and elderly. These variations are responsible of modifications in pharmacokinetics (PK) and 
pharmacodynamics (PD) and thus different drug metabolism and elimination [231]. In addition, 
theoretical effective dosages are calculated on adults and empirically adjusted based on body weight, 
because of the lack of PK/PD study in term and preterm neonates that are characterized by an even 
greater inter-individual variability compared to adults [232] (Figure 23).  
 
For these reasons, quantitative analysis of drugs is needed to better tailor therapy in infants to 
increase efficacy and reduce drug-related toxicities [233]. However, therapeutic drug monitoring 
(TDM) requires large blood volumes that need to be drawn very frequently according to therapy 
protocols. By contrast, current guidelines from the Department of Health and Human Services 
recommend not to exceed a 2.5% of total blood volume/draw or 5% of total blood volume in a 30-
day period. In order to reduce sample volume needed, microsampling techniques, such as dried blood 
spot sampling (DBS), have been developed for various analytical testing in neonates [234,235]. To 
date, DBS analysis coupled with liquid chromatography tandem mass spectrometry (LC-MS/MS) is 
the most common technique for detection of biomarkers in newborn screening studies, TDM, or illicit 
drug detection [235,236].  
In pediatric population, age and body weight are highly related to PK parameters, such as 
body size and composition or liver and kidney functions. These physiological changes are responsible 
of variations in drug absorption and elimination in absence of other comorbidities or concomitant use 
Figure 23. Pediatric age groups 
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of various medications [231]. For example, in neonates, gastric pH is higher than adults (5 in 
newborns vs 2-4 in infants vs 1-2 in young adults) and acid gastric secretions are even lower in 
preterm compared to term neonates. In addition, milk intake increases alkalization of gastric pH. The 
higher pH negatively or positively influences drug absorption by increasing the ionization of 
molecules according to the acid/base balance. Indeed, most of the drugs, are weakly acidic or basic, 
such as β-lactams, and are highly absorbed in neonates; while acidic molecules, such as nalidixic 
acid, are less absorbed due to their presence in the ionized form. A slower gastric emptying or a larger 
extracellular and total body water space also lead to increased drug adsorption and distribution 
[232,237,238]. Other parameters that influence PK in neonates are: immaturity of the intestinal 
microbiota; reduced total area of intestinal mucosa; decreased activity of pancreatic enzymes; less 
concentrated bile acids; and a different bloodstream flow compared to adults [239]. In case of 
intramuscular administration, newborns have a reduced and delayed absorption of the drug because 
of a decreased perfusion, rate of passive transport through the endothelium or distribution volume. 
Moreover, newborns have a greater instability in vascular motility and a lower muscular mass and 
subcutaneous fat which contribute to the reduced absorption of the drug through intramuscular 
injections.  
The distribution volume of a drug is also influenced by the total binding capacity of plasma 
proteins and by total body water space which continually change within the first years of life. In 
newborns, the total binding capacity of proteins is reduced because of lower levels of albumin or the 
presence of endogenous compounds, such as bilirubin, which compete for protein bindings. As a 
result, drugs have an increased circulating unbound fraction and, subsequently, a higher distribution 
volume [240].  
Drug elimination is reduced in newborns because of the immaturity of liver and kidney 
functions. Phase I (hydroxylation, deacetylation and oxidation) and phase II reactions (conjugation) 
in the liver and glomerular filtration rates and tubular secretion in the kidneys are greatly reduced in 
newborns and even more in preterm neonates. Methyltransferase and sulfotransferase activities are 
increased in newborns; while, glucuronyl transferase and N-acetyltransferase-2 are greatly reduced, 
as well as cytochrome P450 functions are still not completely functioning. As a result, drugs have a 
longer half-life and higher plasmatic concentrations. Liver functions can also be affected by the 
presence of polymorphisms in genes encoding for enzymes related to drug metabolism [239]. Kidney 
functions reach the complete maturity only in late childhood; however, an adequate glomerular 
activity is observed only at 36 weeks of pregnancy, thus preterm neonates have an insufficient kidney 
function [240]. Finally, blood composition, such as a higher hematocrit (42-65%) compared to adults, 






Phenobarbital (PB) (Figure 24), introduced in clinical use in 1904, is one of the oldest effective 
anticonvulsants. PB, an anti-barbiturate with low toxicity, acts through the synaptic inhibition of 
GABA and by increasing the activation of the GABAA receptors leading to central nervous system 









To date, PB remains an effective and safe anticonvulsant drug for prevention and treatment of 
neonatal seizures with a better efficacy and safety profile compared to other anticonvulsants, such as 
phenytoin and benzodiazepines [244]. The loading dose is 20 mg/kg intravenously and the 
maintenance dose is 3 to 4 mg/kg per day administered 12 to 24 hours after the loading dose. The 
therapeutic concentrations are 15-40 mg/mL. Non-responders generally receive additional doses of 5 
to 10 mg/kg bolus and neonates with refractory seizures receive an additional dose up to a maximum 
plasma concentration of 100 mg/mL [245]. This therapeutic strategy allows the seizure control in 
77% of newborns [246]. Even though PB has a safe profile, through concentrations > 40 mg/mL can 
cause sedation, hypotension, arrhythmia, cerebral hypoperfusion and respiratory depression.  
 PB is metabolized by the cytochromes CYP2C9, CYP2C19, and CYP2E1 and conjugated 
metabolites are eliminated by the kidney; however, this drug is a strong cytochrome inducer causing 
decreased plasma concentration within 1-2 weeks of treatment [242]. PB has a long half-life (80-120 
h) which is even longer in preterm infants which show also a higher distribution volume [247,248]. 
Body weight and distribution volume positively also correlate with total clearance of PB, which 











Methylxanthines, such as caffeine (Figure 25), are used for the treatment of apnea of 
prematurity (AOP) [250-255]. Caffeine has largely replaced other methylxanthines and is among the 
most used medications in preterm infants [256,257]. Caffeine, an adenosine receptor antagonist, 
stimulates the CNS by modulating several neuronal signaling pathways, such as noradrenaline or 









Very-low weight newborns (<28 weeks gestation or <1000 g) have an increased risk of apnea 
episodes and bronchopulmonary dysplasia (BPD), a chronic respiratory disease caused by respiratory 
distress syndrome and with high mortality and long-term pulmonary and neurodevelopmental 
morbidities. AOP is caused by the immaturity of respiratory control mechanisms, and the incidence 
is widely variable and is based on gestational age and birth weight [259-265] Since frequent apnea 
episodes can alter cardiorespiratory functions and neurocognitive development, caffeine is 
recommended for prevention and treatment of apnea events in preterm [266]. Indeed, early use of 
caffeine significantly reduces the incidence of BPD and the duration of respiratory assistance. 
The loading dose is 20 mg/kg with slow intravenously infusion and the maintenance dose is 
of 5 mg/kg per day and can be increased at 10 mg/kg, if required. This protocol allows to reach the 
therapeutic range of 10-20 mg/kg [267,268]. AOP is not common after 34-week gestation, caffeine 
therapy should be continued until preterm infants are 34 to 36 week corrected gestational age and free 
of any apnea episodes for at least 8 days [269]. However, late discontinuation at 40 weeks can 
significantly reduce apnea episodes in preterm infants compared to standard discontinuation at 34-35 









5.1.4. Project aim 
 
In preterm infants, caffeine is employed for prevention and treatment of AOP; while PB is 
used for treatment and prevention of seizures. More than 50% of newborns are unresponsive to 
therapy and need additional loading doses; by contrast, higher PB levels can cause respiratory 
depression. TDM, a laboratory practice for measurement of serum/plasma drug levels, allows dose 
adjustment to minimize PB side-effects. However, TDM requires frequent blood drawing not feasible 
in preterm infants. Microsampling techniques, such as DBS, can minimize sample volume needed 
per analysis and could be a good sampling choice for TDM in newborns. In this part of my PhD 
thesis, we developed and optimized a DBS microsampling – LC-MS/MS method for the measurement 




5.2. Materials and methods  
5.2.2. Chemicals and reagents 
 
Formic acid. UHPLC grade water and methanol (MeOH) were purchased from Romil 
(Waterbeach Cambridge. UK). Caffeine. internal standards (IS) (Primidone. PRM; and caffeine C13. 
C13) and filter paper were from Sigma-Aldrich (St Louis. MO. USA). Phenobarbital (PB) solution 




Samples were obtained from neonates admitted to the Neonatal Intensive Care Unit. 
University Hospital “San Giovanni di Dio Ruggi d’Aragona”. Salerno (Italy). Whole blood was 
collected by heel puncture and was directly deposited on filter paper. DBS were then placed in 
appropriate bags, transported to our laboratory, stored at +4°C and processed within 24 hours. 
 
5.2.4. Preparation of stock and working solutions 
 
Phenobarbital (PB) sodium solution for injection at initial concentration of 100 mg/mL was 
diluted to 10 mg/mL in physiologic solution (stock solution). Stock solutions for PRM and C13 were 
prepared in 100% MeOH at 1 mg/mL; while. caffeine was diluted at 1 mg/mL in physiologic solution. 
Work solutions were at 1 mg/mL in physiologic solution for PB and at 10 µg/mL in MeOH 100% for 
PRM. Caffeine and its isotope were diluted in physiologic solution at 250 μg/mL and in H2O at a 
concentration of 10 μg/mL. All working solutions. as well as the initial stocks. were stored at -20°C. 
 
5.2.5. LC-MS/MS conditions 
 
LC–MS/MS apparatus consisted of a Ultimate 3000 UHPLC system (Thermo-Fisher. 
Waltham. MA. USA) coupled with a TSQ endure mass spectrometer (Thermo-Fisher) equipped with 
an electrospray ion source and a triple quadrupole ion analyzer. Chromatographic separation of 20 
µL to PB and 5 µL to caffeine was carried out using a Luna-Ω C18 Polar column (2.1 x 50 mm. 1.6 
μm) and a mobile phase composed of a mixture of 0.1% formic acid in water (A) and 0.1 % formic 
acid in acetonitrile (B). An elution gradient ranged from 35% to 49.5 % of B in 0.7 min at 30°C for 
PB and from 5% to 20% of B in 1 min for caffeine. The flow was set at 0.4 mL/min. 
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Spectra were acquired in negative selected reaction monitoring (SRM) mode for PB and in 
positive SRM mode for PRM. Specific transitions were selected by direct injection in order to 
maximize selectivity and sensitivity: for PB. 230.8→188 and 230.8→85 with a collision energy (CE) 
of 10 V and an RFlens of 90; for PRM. 219.9→163 with a CE of 12 V and a RFlens of 85; for 
caffeine. 195→138 and 195→110 with CE of 23 and 22V. and RFlens of 134; for C13. 198→140 
with CE of 18V and RF lens of 142 (Table 17 and Figure 26-27). 






















Phenobarbital 229.8 230.8 
188 10 90 
85 10 90 
Primidone 218.9 219.9 
163 12 85 
138 23 134 
Caffeine 194 195 
138 23 134 
110 22 134 
Caffeine C13 197 198 140 18 142 

















5.2.6. Samples preparation 
 
Ethylene Diamine Tetraacetic Acid (EDTA) blood samples were obtained from healthy 
volunteers recruited at the Blood Bank of the University Hospital “San Giovanni di Dio Ruggi 
d’Aragona”. Salerno (Italy). Briefly. 20 µL of whole blood were blotted on filter paper and air-dried 
at RT for 2 hours. Then DBS were cut out, placed in a 2 mL safe-lock tube and rehydrated with 50 
μL of PRM at a final concentration of 100 ng/mL in UHPLC grade water. After vortexing, samples 
were incubated in a water bath at 37° C for 10 min, and then 200 μL of 80% MeOH were added, 
vortexed for 20 seconds and sonicated for 10 min. Supernatants were transferred to a clean tube and 
centrifuged at 17.000g at 4°C for 10 min. and 100 μL of clear supernatant placed in vials for LC-
MS/MS analysis. 
 
5.2.7. Method validation 
 
The absence of carry-over was accepted when the signal for a certain analyte was less than 
20% of the LLOQ and less than 5% for the IS. No carry-over was detected. Selectivity was assessed 
by analyzing whole blood samples without analytes but with other commonly used drugs, samples 
spiked with analytes at the LLOQ, and samples spiked with IS. Based on the EMA guidelines, the 
absence of interfering molecules is accepted when the signal at the same retention time of the target 
drug is less than 20% of the LLOQ for the analyte and less than 5% for the IS. For all analytes used 




in our method, there were no interfering compounds. Specificity was evaluated based on the 
consistency of the retention time for a certain analyte across runs and the presence of both products 
(quantifier and qualifier) in a constant ratio for a precursor. Our method showed high specificity for 
each analyte. The matrix effect (ME), defined as modifications in ionization recovery of target 
analytes, is caused by the presence of interfering compounds present in the same matrix and co-
eluting with studied molecules eventually leading to ion suppression. The FDA guidelines for 
validation of analytical procedures recommend evaluation of ME by post-column infusion of target 
analyte or post-extraction addition. In our case, we evaluated ME by comparing peak area of 
analyte/IS ratios in QC samples spiked after extraction to pure solutions at the same concentrations. 
LLOD and LLOQ were defined as described in paragraph 2.2.6. For their estimation, samples 
were prepared at concentrations of 0.01. 0.025. 0.05. 0.1. 1 and 2 µg/mL and analyzed in triplicates. 
Linearity was determined by plotting peak area of analyte/IS ratios as a function of the analyte 
concentration. and by fitting the curve to a linear regression. Experimental concentrations were back 
calculated using calibration curves to determine their deviation from nominal values. 
For calibration standards, PB at final concentration of 100 µg/mL was freshly prepared in 
whole blood and serial dilutions (1. 5, 12.5, 25. 50 and 75 µg/mL) were obtained by using whole 
blood with a 10 % of dilution ratio with physiological solution. For caffeine. serial dilutions (0.05, 
0.25, 1, 2, 4, 8, 16 e 32 µg/mL) were prepared in whole blood at 12.8% of physiological solution. 
Then 20 µL of each concentration were spotted on DBS and extracted as described above.  
The average recovery of PB from DBS was determined by comparing experimental 
concentrations measured in three samples as pre- and post-extraction process. Pre-extraction samples 
were obtained by directly adding PB or caffeine in whole blood at specific amounts (1, 20 or 50 
µg/mL for PB and 0.2, 3.2, 24 µg/mL for caffeine); post-extraction samples were prepared by spiking 
into an extracted matrix from DBS the amount of analytes required to obtain the desired concentration. 
Mean recoveries were calculated as the percentage difference between the quantity of PB recovered 
from the post-extraction and pre-extraction samples divided by the quantity of the PB spiked (post-
extraction). 
Intra-day and inter-day PB precision and accuracy of the method were evaluated at three 
different concentrations (3, 20 and 70 µg/mL) in samples extracted from DBS. For caffeine. precision 
and accuracy were evaluated at high (6, 12, 18, and 24 µg/mL) and low concentrations (0.2, 0.8, and 
3.2 µg/mL). Three replicates for each concentration were extracted and analyzed twice in the same 
day (T0) and after 3 or 6 hours (T3 and T6, respectively). Aliquots of those samples were stored at 
+4°C and analyzed again (three times per day) after 24 (T24) and 48 (T48) hours. Percentage of 
coefficient of variance (%CV) was calculated for assessing precision and the percentage relative error 
(% RE) for accuracy. 
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To estimate samples stability on DBS, different conditions were evaluated for 3 
concentrations: 3, 20 and 70 μg/mL for PB; and 0.25, 2 and 16 μg/mL for caffeine. DBS were directly 
placed in the fridge after blood spotting or left at RT for 2 hours and then placed at +4°C. Samples 
from both conditions were extracted and analyzed at T0, T24, T48 and after 15 days. In addition. 
samples were left at RT overnight and then extracted. Stability was evaluated by monitoring 
modifications in the relative peak intensities. 
 
5.2.8.  Comparison between DBS and plasma 
 
To evaluate the correlation between plasma and DBS, PB or caffeine were added to whole 
blood at concentrations used for calibration curve. Afterwards, 20 µL of whole blood were directly 
spotted on filter paper while 250 of the same blood samples were centrifuged at 3000g at 4°C for 10 
min and plasma collected. Then 50 µL for PB or 45 µl for caffeine of plasma were transferred to a 
clean tube and IS added at a final concentration of 5 µg/mL. Extraction was carried out adding 200 
µL or 250 µL, for PB and caffeine respectively, of methanol to samples. After 30 min incubation at 
RT with a vortex step every 10 minutes, specimens were centrifuged at 4°C and 17000g for 5 min. 
An additional centrifuge step at 4°C at 17000g for 1 min was performed and supernatant was 





5.3. Results and discussion 
 
As a first step for method optimization, we tested several chromatographic conditions for an 
optimal separation of the targeted compounds. A mobile phase composed of 0.1% formic acid in 
water (solution A) and 0.1% formic acid in acetonitrile (solution B) was employed, and an elution 
gradient from 35-49.5% of B in 0.7 min for PB and from 5-20% of B in 1 min for caffeine was used 



























Before LC-MS/MS analysis, body fluid samples should be cleaned up from lipids. proteins 
and salts to remove interferers and to avoid column damages. In addition, the use of DBS sampling 
Figure 28. PB and PRM chromatograms  
 




has several pre-analytical variables that need to be investigated during method optimization, such as 
blood spot volume for example. We first evaluated extraction procedure from DBS using a 100% 
methanol extraction as previously described [275]. After centrifugation. samples were dried at various 
temperatures in Speed Vac or under nitrogen flow. Pellets were then resuspended in MeOH from 10 
to 100% concentration with or without 0.1% formic acid. Comparing the different conditions used, 
we found that the better results in terms of extraction yield were obtained when DBS were first 
rehydrated and then extraction was carried out using 80% methanol. Using this protocol. extraction 
yields for PB ranged from 65.5 to 85.3%. and for the IS was of 95.6% (RSD = 2%) (Table 18).  
 
 






 CV (%) 
RSD 
(%) 
 CV (%) 
RSD 
(%) 
Phenobarbital  65.5 19.0  80.1 4.2  85.3 3.1 
Table 18. Extraction yields for PB at various concentrations.  
 
For caffeine. extraction yields ranged from 67.8 to 145% (Table 19); these high values rates 







Table 19. Extraction rates for caffeine.  
 
We then validated the method based on the EMA guidelines. First, selectivity was assessed; 
the absence of interfering molecules is accepted when the signal at the same retention time of the 
target drug is less than 20% of the LLOQ for the analyte and less than 5% for the ISTD. Our analyses 
showed the lack of interfering compounds. Specificity was evaluated based on the consistency of the 
retention time for a certain analyte across runs and the presence of both products (quantifier and 
qualifier) in a constant ratio for a precursor. Our method showed high specificity for each analyte. 
LLOD and LLOQ were defined according to the EMA guidelines. In our case. LLOQ was identified 
at 1 μg/mL for PB and 500 ng/mL for caffeine. Next, linearity was assessed using six concentrations 




0.2 145 ± 7.3 
3.2 82.9 ± 0.8 
24 67.8 ± 2.5 
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of analyte concentrations, and then fitting the data to a linear regression. For PB, the linear range was 












Precision and accuracy of the method were then investigated as previously described. For PB, 
%CV and %RSE were <15% for all concentrations of the quality controls (Table 20). For caffeine, 
the presence of the compound in the blood of volunteers hampered a reliable assessment of precision 
and accuracy of the method.  
 
 INTRADAY  INTERDAY 
Concentrations μg/ml CV% RSE%  CV% RSE% 
3 7.23 5.16  9.36 2.12 
20 3.63 3.57  7.36 2.98 
70 5.46 26.02  8.61 23.92 
Table20.Intra- and inter-day precision and accuracy of PB  
 
Short- (24 and 48h) and long-term (15 days) stability was investigated for PB at various 
concentrations (3, 20 and 70 μg/ml) from DBS samples stored at +4°C right after spotting blood on 
filter paper or after 2h air-drying. Samples were then extracted and analyzed at 24/48h or 15 days. 











Directly at 4°C Stored at 4°C after drying 
24h 48h 15 days 24h 48h 15 days 
3 17.6 -14.8 -75.5 -1.4 10.6 -73.1 
20 -11.1 -5.6 -77.1 -11.1 0.3 -79.9 
70 -7.5 -5.8 -83.6 -11.6 0.2 N.d. 
Table21.Stability of PB in different storage conditions. 
 
We also investigated the stability of extracted samples stored at +4°C and analyzed at 3, 6, 
12, 24 e 48 h (Table 22). All samples were stable except for specimens with PB at 3 μg/mL after 48h 







Table22. Stability of PB 
 
For caffeine, quality controls were prepared at concentrations of 0.25, 2 and 16 µg/mL, air-
dried for 1h, and stored at room temperature for 1, 2, 3, 6, 9 and 12 days. DBS were then processed 




Day +1 Day +2 Day +3 Day +6 Day +9 Day +12 
0.25 -2 -2 -5 -28 -89 -47 
2 0 -4 -10 -9 -86 -23 
16 1 0 -10 -9 -87 -12 




Extracted samples stored at +4 °C 
3h 6h 12h  24h 48h  
3 2.59 6.38 10 10.43 17.19 
20 3.9 6.24 8.04 9.52 14.2 
70 8.48 9.33 4.42 11.98 10.87 
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Storage of DBS at +4°C allowed to extend the stability of quality controls at 2 and 16 µg/mL 




Day +1 Day +2 Day +3 Day +6 Day +9 Day +12 
0.25 -5 -7 -6 -30 -23 -27 
2 -1 -3 -6 -8 -9 -7 
16 -2 -24 -10 -5 -15 -12 
Table24. Stability of caffeine at a 4°C. 
 
Reported methods for PB measurement have been optimized for LC-MS/MS analysis from 
plasma samples. For this reason, to confirm the reliability of our method using DBS samples, we 
correlated results from DBS to those obtained from plasma (Table 25). As expected, results from 
DBS samples were similar to those from plasma, thus confirming that this microsampling technique 
might be used as good alternative to peripheral blood drawing.  











Mean SD RSD% 
1  1.1 16.8 0.8 5.1  0.9 0.2 20.6 
20  15.3 6.6 14.2 3.2  14.8 0.8 5.2 
50  45.2 1.1 40.7 3.8  42.9 3.2 7.5 
70  64.2 1.7 78.6 4.9  71.4 10.1 14.2 
Table25.Plasma vs DBS 
 
Finally, our method was validated on DBS samples obtained from preterm neonates admitted 
to the Neonatal Intensive Care Unit, University Hospital “San Giovanni di Dio Ruggi d’Aragona”, 
Salerno, Italy, and under PB or caffeine treatment. DBS samples in duplicate were prepared by 
directly spotting blood on filter paper after skin puncture of the heels. Samples were stored at +4°C 
for 24h before processing and analyzed in triplicate.  
Blood for one neonate was collected for PB measurement (Table 26); however, spot volumes 












1398 96522 0.014 
0.016 0.365 0.001 9.5 1764 102200 0.017 
1565 104456 0.015 
B 
2814 101517 0.028 
0.027 0.632 0.001 2.7 2669 101592 0.026 
2774 103476 0.027 
Table26. LC-MS/MS analysis of neonate treated with PB 
 
For caffeine measurement, three preterm neonates were enrolled (Table 27) and DBS 
sampling performed during maintenance therapy at the caffeine steady-state. Patient 1 received a 
loading dose of caffeine of 40 mg in a 30 min infusion, followed by a maintenance of 10 mg every 
24h. Patient 1 experienced only few events of apnea and oxygen desaturation. Patient 2 had severe 
distress respiratory syndrome and received a loading dose of 23.4 mg in rapid infusion and a 
maintenance dose of 5.8 mg increased to 7.5 mg for prevention of apnea during mechanical 
ventilation. Patient 3 was a very-low weight birth preterm neonate who received mechanical 
ventilation and a loading dose of caffeine of 17 mg and a maintenance dose of 4.5 mg. For all 
neonates, trough caffeine concentrations were within the range of linearity.  
 
UPN Duplicate Area 
Caffeine 





SD RSD (%) 
CAF1 
A 
3465153 86812 39.9 
42.6 3228.8 4.4 10.3 3827241 95011 40.3 
4865548 102079 47.7 
B 
6226659 121573 51.2 
47.3 3579.8 5.6 11.9 4944421 114218 43.3 
10110178 116335 86.9 
CAF2 
A 
1724391 103066 16.7 
20.5 1549.7 3.3 16.3 2307660 107271 21.5 
2526876 109271 23.1 
B 
3144215 104560 30.1 
33.8 2560.1 4.1 12.0 3970257 104159 38.1 
3387016 102046 33.2 
CAF3 
A 
3068617 109626 28.0 
18.9 1433.4 8.3 44.1 1297683 112264 11.6 
1873314 108842 17.2 
B 
2968112 113814 26.1 
26.4 1999.1 3.5 13.1 2615516 113265 23.1 
3406252 113558 30.0 
Table27. LC-MS/MS analysis in newborns treated with caffeine 
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In this study, we have developed and optimized a DBS-LC-MS/MS method for quantitative 
analysis of PB and caffeine in neonates. Our procedure was selective, precise and accurate for 
measurement of these compounds from DBS samples; however, validation on a larger cohort of 





























Personalized Medicine has the potential to tailor therapy with the best response and highest 
safety margin to ensure better patient care. By enabling each patient to receive earlier diagnoses, risk 
assessments, and optimal treatments, PM holds promise for improving health care while also lowering 
costs. The large inter-individual variability in drug response represents a major challenge in drug 
therapy, particularly for drugs with a narrow therapeutic index. This individual susceptibility may be 
due to peculiarity in the genetic sequence. However, many non-genetic factors, such as physiological, 
pathological and environmental factors, may also contribute significantly to the inter-individual 
variability in ADME processes.  
TDM use to monitor the evolution of concentrations in biological fluids would be a 
fundamental tool to address this problem. It is based on the hypothesis that there is a definable 
relationship between the dose of drug administered and its concentration in blood and/or plasma - or 
more generally in biological fluids - and between this concentration and the observed 
pharmacological effects. However, the correlation between dose and concentration of a specific drug 
is not always as linear as it might seem, and is generally characterized by several variables associated 
with its pharmacokinetics. Several therapeutic classes have presently been recognized to benefit from 
TDM including antiepileptics, antibiotics, antimalarials or anticancer drugs, but there are conditions 
suggesting the use of TDM, regardless of the used drug. In particular, when clinical evidences suggest 
a less than expected clinical response to therapy, or if over-dosage is suspected in the presence of 
clinical signs of toxicity. When special patients like pediatric population, are subjected to drug 
therapy, TDM is always advisable. For these populations, the available data on drug effects, toxicity 
and metabolism are generally reduced, because of the limited number of treatments and/or for the 
lack of clinical experimentation. Different analytical approaches have been used so far to measure 
the concentration of a drug and/or its metabolites in biologic fluids or tissues. Liquid chromatography 
(HPLC) and gas chromatography (GC) have been considered for years the "gold standard", in parallel 
with immunometric techniques, for the measurement of specific substances in biological fluids such 
as plasma/blood and urine. However, since 15 years LC-MS emerged for its impressive performances 
and has now became a key analytical tool for all modern clinical laboratories. 
During my Ph.D., we developed and validated some HPLC-based and LC-MS/MS-based 
approaches, aimed to carry out TDM of some drugs in different body fluids. 
We have faced different problems, involving quite different active principles. First, the 
monitoring of drugs with a wide therapeutic window, but characterized by a frequent non-adherence 
to therapy (hydroxychloroquine-HCQ). The analytical method developed, based on the use of a 
widely diffused and medium cost equipment as HPLC, could find wide application in the control of 
patients suffering from chronic pathologies as SLE; for these patients, in fact, the main cause of 
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ineffectiveness of the treatment is the failure to correctly follow the therapeutic indications provided 
by the doctor. 
The well-known problems associated with the use of drugs for anti-tumor therapy and the 
ever-increasing use of such drugs, led us to develop analytical methods aimed at monitoring this type 
of substances. We have therefore developed an analytical method for a new-generation anti-IMF drug 
(Ruxolitinib), believed to be safe, but for which cases of reduced efficacy have been reported. The 
HPLC-based approach developed proved to be efficient and easy to apply and could become a useful 
tool for choosing the correct individual dosage of the drug. It should also be emphasized that there is 
still a limited number of data related to Ruxolitinib safety profile; the availability of an analytic 
method like the one we developed could therefore allow to quickly and effectively increase the 
information on the dose-effectiveness-safety relationship for this drug.  
Remaining in the field of the anticancer tumors, we focused on the TDM of one of the most 
used antiblastic chemotherapeutic drugs, 5-fluorouracil (5-FU). Its high toxicity, and the great inter-
individual variability observed in the susceptibility to this drug, make therapeutic monitoring of 
patients treated with 5-FU mandatory. The a priori assessment of this drug dosage for each individual, 
carried out based on the pharmacogenetic information, does not always guarantee the efficacy and, 
above all, the safety of the therapy. The LC-MS / MS-based methodology we have developed and 
validated is very effective and robust, despite the intrinsic difficulty of analyzing such a small and 
polar molecule as 5-FU. Furthermore, the effective application of our methodology in a clinical 
setting allowed elucidating the molecular basis of some abnormal and unexpected responses to 
therapy. 
Finally, we have started exploring the potential of TDM in the optimization of dosages of 
drugs administered to patients in neonatal age. This category of patients, in fact, is particularly 
susceptible to the risk of uncorrected drug dosage administration, due to multiple factors; first of all, 
the lack of specific information on the suitable amount of drug to deliver, since there are no clinical 
trials conducted on neonates; moreover, the great inter-individual variability that exists between 
patients who have an immature and rapidly evolving organism. From a technical point of view, the 
main difficulty in conducting TDM studies on neonates is the need to carry out analyses on very small 
volumes of biological fluids (especially blood). In our study, we validated an analytical method for 
monitoring drugs widely used in neonatal intensive care, such as caffeine and phenobarbital, based 
on the use of a micro-sampling system (DBS) and LC-MS/MS techniques. The achieved results 
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“tête-à-tête” di fronte all’HPLC e tu mi chiamavi Wilson. Grazie Bru, per avermi insegnato tutte le 
basi dell’HPLC e non solo. Lo so che sarò ridondante come il nostro codice genetico ma volevo anche 
ringraziarti per esserci stato anche al di fuori del laboratorio. Come quando sei corso in ospedale dalla 
tua “Strapagnon”. 
 
Voglio inoltre ringraziare i miei compagni di viaggio il Dr. Albino Coglianese, la Dr.ssa 
Valentina Giudice e la Dr.ssa Viviana Fortunato  che hanno reso ogni giorno di lavoro un 
giorno di piacere condiviso.    
Vale, grazie per il prezioso aiuto nelle numerose traduzioni e riletture ed avermi salvata dalle 
mie cure omeopatiche.  
Albi, grazie di tutto ed anche per tutte le ore di babysitting gratis. Sei una persona piena di 
qualità, rimani come sei. 
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Vivi, grazie per il grande aiuto nella rilettura dei ringraziamenti e di essere stata una attenta 
ascoltatrice, resta quella che sei. 
Francesca anche se abbiamo passato poco tempo insieme, ti ringrazio delle piccole attenzioni 
che hai avuto.   
 
Ringrazio anche tutte le persone che sono state con noi anche solo per un breve periodo, che 
abbiamo avuto la fortuna di formare e che ci hanno permesso di crescere. Marianna, Antonietta, 
Carmela, Marisa, Elena. 
 
Grazie anche all’équipe di farmacogenetica dell’ospedale San Giovanni di Dio e Ruggi 
D’Aragona con cui è sempre stato un piacere condividere del tempo e cibo insieme.  
 
Voglio ringraziare le mie amiche Rossella e Zandra che sono state sempre presenti per me e 
mi hanno permesso di rendere il mio soggiorno in Italia piacevole. 
Rosse, grazie di avermi accolta all’interno della tua famiglia come se ne facessi parte. Ti 
voglio tanto bene. 
Zandra, gracias por los dias que hemos trascorso juntos visitando y descubriendo este 
maravilloso país. Nos vemos pronto para descubrir el tuyo. 
 
Infine, grazie alla mia famiglia e al mio compagno, per avermi seguito nelle mie scelte anche 
al prezzo di pagare grandi sacrifici.  
Une pensiero speciale va a mia madre che ci ha sempre spinti a dare il meglio di noi, che ci 
ha insegnato che nella vita niente è servito su un vassoio d’argento e che se desideriamo qualcosa 
dobbiamo conquistarla. Grazie, Mamma per l’energia che ci infondi e dei tuoi sacrifici per aver fatto 
di noi quelle che siamo ad oggi. Ti amo.   
Chouchou, ti ringrazio per avermi dato la possibilità di realizzare i miei sogni, sostenendomi 
nella realizzazione delle mie ambizioni senza farmi sentire il peso delle mie scelte. So che questi 
ultimi quattro anni, per quanto ricchi e belli possano essere stati con la nascita di nostro figlio e le 
nostre scoperte italiane, sono stati anche il risultato di scelte difficili. Allora grazie di tutto.  
Papà, ti ringrazio di affrontare questo viaggio e di essere presente questo giorno per me.  
Iris e Coline anche se non siamo sempre d’accordo sono molto orgogliosa di avervi come 
sorelle. Vi amo più di tutto. Quindi niente più cadute dalla bici, Ok… 
Nonno, grazie di avermi dato questa “spintarella” all’inizio senza la quale non sarei mai 
partita. Non te l’ho mai detto veramente ma sei una persona molto importante per me. 
 
Mi rimane soltanto di ringraziarvi ancora d’aver condiviso un pezzo della mia vita con me, e 
spero che la storia non finisca qua e che avremmo ancora tante pagine da scrivere insieme. 
 
